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Abstract
Herc5 is a potent HIV-1 restriction factor able to restrict HIV-1 by two mechanisms: 1)
conjugation of ISG15 to gag polyprotein via E3 ligase activity, and 2) restricting the
production of HIV-1 proteins by an unknown mechanism that is independent of its E3
ligase function. Herc5 mutations of the RCCl-like domain (RLD) and Spacer domains
were generated to dissect this mechanism. Based on HIV-1 release assays, the RLD is
important for preventing the production of viral proteins. Herc5 transfected cells show
defects in cell cycle progression at the G2/M phase as well as abnormal nuclear
morphology. C994A and ASpacer constructs did not impact these phenotypes. However,
ARLD Herc5 constructs had normal cell cycle and nuclear morphology. Based on the
results found, the RLD was found to be an important mediator of Herc5 cellular and
antiviral activity.
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Chapter 1: Introduction
1.1 Overview of Ubiquitination
Ubiquitination of proteins has a large role in maintaining homeostasis in the host
by altering a wide variety of cellular processes such as, apoptosis, cell cycle, DNA
transcription, and antiviral immune responses. The conjugation of ubiquitin to target
proteins requires three enzymatic reactions from three classes of enzymes, the E l, E2,
and E3, in sequential steps [1]. The initiation of this process involves the activation of
ubiquitin by E l through an ATP dependent mechanism, forming a ubiquitin-adenylate
intermediate and results in binding to a cysteine residue of the E l via a thioester bond.
This activated ubiquitin is then passed to a cysteine residue on the E2 enzyme via a transthiolation reaction. The E2 then passes ubiquitin to an E3 ligase enzyme which
conjugates the c-terminus of ubiquitin to a lysine residue on a target protein. The process
of ubiquitination can lead to formations of poly-ubiquitin chains on target substrates. The
length and binding site of the poly-ubiquitin chain on the substrate can have a variety of
affects including alternative protein trafficking, degradation, or signalling events to occur.
The variety of ubiquitin linkages derives from the diversity of E l, E2, and E3 enzymes
that are able to conjugate ubiquitin to targets, E3s being the most diverse class amongst
ubiquitinating enzymes with over a hundred known E3 ligases [2,3],
There are two main classes of E3 ligases: RING (Really Interesting New Gene)
domain E3 ligases and HECT (Homologous to the E6-AP Carboxyl terminus) domain.
These two classes differ in the way they interact with ubiquitin and their target substrate
[3]. RING E3 ligases act as scaffold proteins, binding both E2 and substrate protein,
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which brings them in close proximity to one another and facilitates the direct transfer of
ubiquitin from the E2 to the target substrate. HECT (Homologous to the E6-AP (ube3A)
Carboxyl Terminus) domain E3 ligases however, form an E3-ubiquitin thiol-ester
conjugate intermediate. In this instance, ubiquitin is transferred from the E2 enzyme to
the HECT E3 ligase which then catalytically conjugates ubiquitin to the amine group of a
lysine residue on a bound substrate, the specifics of which are unknown [3]
(Supplementary Figure 1). For substrate proteins to be capable of accepting ubiquitin
each must contain either a ubiquitin associated domain, ubiquitin interacting motif,
ubiquitin E2 variant or CUE-1 homologous sequence. Each of these ubiquitin binding
domains is commonly affiliated with specific protein and cellular activities such as
ubiquitin linkage patterns, DNA repair, degradation, and signalling which may in part be
responsible for the diversity of ubiquitin functions [4-6].
1.2 HECT E3 ligases
HECT domain containing proteins were first discovered in E6 associated protein
(E6-AP), a cellular factor which associates with the Human Papilloma Viruses 16 and 18
(HPV16 and HPV18). This HECT domain containing protein targets p53 for
ubiquitination and proteasomal degradation which enhances viral replication for HPV16
and HPV18 [7,8]. Sequence analysis of the C-terminus of E6-AP shows 28 proteins
containing similar C-terminal sequences which formed a new class of proteins
subsequently designated HECT domain containing proteins [9]. C-terminal HECT
domains perform the catalytic function of conjugating ubiquitin on to its target substrates,
while the N-terminus of most HECT containing proteins are reserved for recognizing and
maintaining substrate specificity [10-12]. These N-terminal regions of HECT containing
-2-

proteins are subcategorized into three different groups: 1) RLD (RCCl-like domain)
containing HECT proteins, 2) WW domain containing HECT proteins called
NEDD4/NEDD4-like E3s, and 3) Singular HECT proteins which neither contain an RLD
or a WW domain [13-15],
The precise mechanism by which the HECT domain conjugates ubiquitin to a
substrate remains unclear. However, all HECT E3 ligases have at least 4 biochemical
activities: i) they bind to specific E2s ii) they form ubiquitin-thioester intermediates on
their active-site cysteine when ubiquitin is transferred from the E2 iii) it conjugates
ubiquitin on lysine residues of target proteins by catalyzing the formation of an isopeptide
bond iv) it conjugates additional ubiquitin molecules on the lysine residues of the already
conjugated ubiquitin forming a chain [16], Crystal structure analysis of the HECT
domain of E6-AP shows that the HECT is a bi-lobed structure made up of the N-lobe and
the C-lobe which are connected by a flexible hinge made up of 3 amino acids. This
structure is maintained through most HECT domain containing proteins and is important
for the catalytic activity of the domain as well as its interaction with a specific E2. The
N-lobe of the E6-AP HECT domain forms a V shaped groove which is responsible for
interaction with its E2, UbcH7, while the C-lobe contains the active-site cysteine residue
responsible for accepting the ubiquitin transfer [16]. Once the UbcH7 is bound to the
groove of the N-lobe, the active-site cysteine residues on both UbcH7 and E6-AP are
only 41A apart and have an open line of sight between them for the easy transfer of
ubiquitin. Interestingly it has been proposed that the N-lobe binding of the E2 is stable
and is maintained throughout the entire E1-E2-E3 enzymatic cascade facilitating the
efficient transfer of ubiquitin.
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This bi-lobed HECT domain structure is clearly an important feature for the
proper functioning of HECT proteins such as WWP1. Two models have been proposed
to describe how the HECT domain structure relates to the mechanism by which WWP1
HECT E3 acts to ubiquitinate target substrates. 1) the C-lobe rotates along the hinge
region and acquires ubiquitin molecules from the bound E2 on the N-lobe via a thioester
bond and tethers to the active- site cysteine residue which subsequently modifies the
target protein through a isopeptide bond. This continuously occurs until the growing
ubiquitin chain interferes with the flexibility of the hinge region and consequently
interrupts further ubiquitination. 2) Ubiquitin chain elongation occurs before the
conjugation of the poly-ubiquitin chain on the target protein. Here the transfer of
ubiquitin from the E2 to the E3 occurs in the same fashion as the first model but differs in
that it proposes that the ubiquitin chain forms on the active-cysteine residue on the C-lobe
of the HECT domain. The C-lobe continuously rotates along the hinge region to bring
the C-lobe lysine residues of attached ubiquitin within close proximity of the thioester
bond between the E2-ubiquitin conjugate on the N-lobe. This consequently forms the
ubiquitin chain and stops when the ubiquitin chain interferes with the flexibility of the
hinge region. This poly-ubiquitin chain is collectively transferred to the target protein in
one step [17].
It has been noted repeatedly in literature that different HECT domains favour
certain conformations of ubiquitin chains. For example, E6-AP favours K48 linkages of
ubiquitin (linkages of ubiquitin at the 48th residue-lysine) which subsequently leads to
proteasomal degradation of these protein targets [18,19]. In contrast, the HECT proteins
NEDD4 and Itch have been shown to favour K63 linkages of ubiquitin (chains of
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ubiquitin linked at the lysine residue at the 63rd amino acid) for proteasome-independent
processes such as DNA repair, endocytosis, and NF-kB activation [20,21]. Mutational
analysis suggests that the C-lobe of HECT domains carries the specificity for these
various ubiquitin linkages. Chimeras in which the C-lobe and linker of the HECT
domain of the protein Rsp5 (typically promotes K63 linked ubiquitin chains) are replaced
with the C-lobe and linker of E6-AP (favouring K48 linked ubiquitin) show almost
exclusive production of K48 linked ubiquitin chains on target proteins [22]. When only
the C-terminal portion of the C-lobe of Rsp5 was replaced with the C-terminal portion of
the C-lobe of E6-AP, the same K48 linked ubiquitin chains were formed again almost
exclusively. This data which strongly suggests this C-terminal region (60 amino acids) of
the C-lobes of Rsp5 is responsible for the patterns of ubiquitinylation [22] however it is
unclear whether this parallels all HECT domains.
The regulation of the function of E3 ligases especially HECT E3s is
physiologically crucial in maintaining human health. For example, disregulation of the
E6-AP HECT domain containing protein in which there is inappropriate activation of the
E3 ligase has been linked to the development of cervical cancer. The highest risk factor
for the development of cervical cancer is HPV. One of the most effective modes of
restricting HPV replication is through the tumour suppressor protein p53 [10]. For
efficient replication of HPV the E6 protein, encoded in the viral genome, hijacks the
cellular protein E6-AP which together promote the recognition, binding, and
ubiquitination of p53 leading to its proteasomal degradation and enhancing viral
replication [23].
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The onset of Liddle’s Syndrome is also due to disregulated ubiquitination. This
disease is characterized by high blood pressure and low levels of aldosterone and renin
due to an excessive reabsorption of sodium from the nephron in the kidneys. The
disregulation in reabsorption is due to a high number of epithelial sodium channels on the
apical side (facing the urinary tract) causing an increase influx of sodium back into the
body. These channels are made up of three homologous transmembrane subunits, a, p,
and □. The C-terminus of each of these subunits has a PY motif which allows for the
binding of the WW domains of NEDD4-1 and NEDD4-2 HECT domain containing
proteins and ubiquitination of the N-termini of the subunits leading to the sequestration of
the channel and degradation. In Liddle’s syndrome patients, the gene encoding either the
P or □ subunit is mutated causing a deformed or deleted PY motif which subsequently
eliminates NEDD4-1 and NEDD4-2 binding and leads to an accumulation of epithelial
sodium channels at the membrane [10,24,25]. This excessive sodium retention causes
constipation, fatigue, heart palpitations, and chronic hypertension.
1.3 Ubiquitin-like proteins/ modifiers
Similarly to ubiquitin, other posttranslational modifications exist which alter
proteins using the same E1-E2-E3 enzyme cascade reaction. This constitutes a growing
family of proteins called ubiquitin-like modifiers (Ubls). ISG15 was the first and least
characterized protein of this family of proteins. These proteins do not share much
sequence homology with ubiquitin however some show a great amount of structural
similarity. Ubls also are functionally distinct from ubiquitin. Although they may be
involved in protein degradation, they have a diverse range of regulatory functions
including, protein stability, altering protein affinity, or changing localization.
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1.31 SUMO (Small Ubiauitin-like Modifier)
The process of SUMOylation (conjugation of sumo on proteins) has a variety of
functions in the cell including cell cycle regulation, transcription, localization,
localization, degradation, and chromosomal organization [26]. Before conjugation, a pro
form of SUMO is cleaved at the C-terminus by SUMO specific proteases (SENPs) to
create activated SUMO. From this stage, the heterodimer Uba2/Aosl binds SUMO in an
ATP dependent manner, acting as its E l enzyme. The E l dimer then passes SUMO to
its E2 enzyme, Ubc9 - the only known E2 for SUMO, and is attached to an active-site
cysteine residue (similarly to ubiquitin). Ubc9 then interacts with one of a number of
different E3 ligases found for SUMO.
Two-thirds of SUMOylation target proteins contain at least one yKxE/D motif
where \y represents a large hydrophobic residue such as valanine, leucine, or methionine,
and x is any residue. It is possible that the pool of SUMOylatable proteins is much larger
than previously thought seeing as one-third to half of human proteins contain this motif
[27,28]. Currently most SUMOylatable proteins are found in the nucleus. Some of these
proteins are involved in repressing DNA transcription by binding to transcriptional
inhibitors/co-repressors of transcription and enhancing their function or by binding to
transcription factors and co-activators and inhibiting their activity [29,30,40].
Some nuclear SUMOylated proteins are involved in RNA editing by co-localizing
with the RNA editing protein, ADAR1. ADAR1 functions to destabilize dsRNA through
the conversion of adenosine into inosine. Since inosine functions as a guanosine during
translation, the conversion of adenosine into inosine leads to amino acid changes and
results in alterations of protein function, and alternative RNA splicing [31,32].
-7-

SUMOylation of proteins has also been shown to counteract their ubiquitination
and subsequent degradation. The E3 ubiquitin ligase and tumor suppressor protein
vonHippel-Lindau (VHL) has been shown to be regulated by both SUMOylation and
ubiquitination. One of VHLs most researched targets is H IFla, a transcription factor
leading to the upregulation of cyclinDl, the progression of cell cycle, and related to
tumorigenesis [38]. Ubiquitination of H IF la by VHL has been shown to destabilize the
protein and lead to its degradation and protection against tumorigenesis [38, 39].
However, mutations in VHL or hypermethylation in its gene can lead to the development
of renal cell carcinomas and sporadic hemangioblastomas of the CNS due to increased
levels of H IF la [39]. The lysine residues at position 171 and 196 of VHL are targeted by
both ubiquitin and SUMO and are the main regulators of the protein; where
ubiquitination leads to its degradation and SUMOylation causing increased stability [38].
Moreover, SUMOylation of VHL is able to out-compete ubiquitin for binding at these
lysine residues and stabilize VHL expression. This may in part be due to the alternative
trafficking patterns of ubiquitinated versus SUMOylated VHL. It is possible that the
ubiquitination of VHL leads to proteasomal degradation in the cytoplasm as opposed to
SUMOylated VHL which is stabilized and maintains transcriptional regulation within the
nucleus [38].
Upon recognition of ssRNA viruses (like Human Immunodeficiency Virus [HIV]),
RIG-I activates itself by unfolding from an autoinhibitory conformation, a process
initiated by ubiquitination of the lysine residue at position 172. After which, RIG-I
induces a cascade of reactions that lead to the transcription and production of interferon
(for more information on interferon, see section 1.5). It has been suggested that
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SUMOylation of RIG-I has a positive regulatory affect on the activity of the protein.
Particularly, SUMOylation of RIG-I increases its ubiquitination and enhances activation
and interaction with the downstream adaptor protein, cardif which also enhances
expression interferon [45].
Many viruses however have their own means of circumventing these cellular
defences or even utilizing SUMOylation for their own benefit. For example, the nonstructural protein 1 (NS1) of Influenza A is essential for efficient replication of vims in
human cells. Particularly, NS1 antagonizes the interferon response [41]. It does so by
binding to viral ssRNA and sequestering it so that ssRNA binding proteins like RIG-I are
less readably activated by viral RNA and therefore impedes interferon mRNA production
[42] , NS1 is also able to impede the translation of interferon mRNA through the
formation of an inhibitory complex with specific nuclear mRNA export proteins as well
as proteins which form the nuclear pore thus trapping mRNA in the nucleus and
preventing access to cytoplasmic ribosomes. Therefore the production of interferon is
disrupted at two stages by the NS1 protein, at the transcription level as well as translation
[43] . It has recently been shown that the C-terminus of NS1 is SUMOylated at lysine
residues K219 and K221 and contributes to protein stability. It has also been shown that
SUMOylation of NS1 also marginally increases the replication rate of H5N1 and viral
titres [44],
1.32 NEDD8 (Neural precursor cell expressed, developmentallv down-reeulated
81
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Of all ubiquitin like proteins (Ubls), NEDD8 shows the highest degree of
sequence similarity to ubiquitin (-60%). Like the E l for SUMO, the NEDD8 El is a
heterodimer composed of the proteins, APPBP1 and Uba3. Like ubiquitin and SUMO,
NEDD8 is transferred via thioester bonds to the E2, Ubcl2, and the E3 ligase (of which
there are no specific NEDD8 only ligases) [46]. The most well characterized NEDD8
target is the cullin family of proteins. Cullins are scaffold proteins for the SCF
(Skpl/cullin/Fbox) complex, a multi-subunit ubiquitin E3 family. The SCF family of E3
ubiquitin ligases are predominantly involved in the regulation of cell cycle progression,
proteasomal degradation, and transcriptional regulation. The Rbx E3 ligase is a dual
conjugating ligase as it also acts to conjugate NEDD8 to cullins. NEDD8 modification of
cullin by Rbx subsequently enhances SCF mediated ubiquitination as well as increased
proteasomal degradation. NEDD8 modification of cullin aids in the recruitment of the E2
enzyme, ubc4, to the SCF complex and accelerates their association by increasing Ubc4
affinity for SCF [47,48,49],
Since many SCF E3 ligases are essential for cell cycle progression it is no wonder
that NEDDylation is also a required for cell cycle. In mice lacking Uba3, one of the
proteins of the NEDD8 E l enzyme, mitotic and endoreduplicative cell cycle events are
arrested [51]. Endoreduplication involves the replication of the nuclear genome in the
absence of cell cycle progression and leads to a build up of nuclear gene content. The
significance of this phenomenon is currently speculative, however some suggest that in
embryogenesis endoreduplication is responsible and necessary for a mass production of
proteins that are required for the high metabolic demands of the developing fetus [50]. It
has also been shown to be involved in DNA damage resistance and cell differentiation.

-
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NEDDylation of cullin 1 and cullin3 of different SCF E3 ligases are required for the
transition of mitotic cell cycle to endoreduplicative cell cycle and the continuance of
endoreduplicative cell growth [51]. Fetal mice lacking NEDDylation capabilities died in
utero at the preimplantation stage of embryogenesis due to a number of complications
relating to DNA damage and even carcinogenesis [51].
Interestingly certain viruses have evolved to incorporate NEDD8 sequences into
their genome. Bovine Viral Diarrhea Virus (BVDV) is a positive sense (+) ssRNA virus
made up of one open reading frame which codes for a large polyprotein that is cleaved to
form 14 different structural and non-structural viral proteins. The insertion of the
NEDD8 sequence into the p821 strain of BVDV occurs between the third and fourth
codons of the NS3 gene and subsequently leads to a different N-terminal amino acid
sequence. It has been shown that this insertion of NEDD8 into the NS3 sequence acts as
a processing signal to yield NS3, an RNA helicase necessary for the synthesis of the
negative sense RNA strand and infectious virus particles[52,53].
1.33 ISG15 (Interferon Stimulated Gene 15)
(Refer to section 1.52)
1.4 HIV replication
1.41 Virus structure
HIV is an enveloped virus with two (+) ssRNA genomes that belong to the virus family
Retroviridae or retroviruses. This class of virus is unique in that their ssRNA genomes
are converted into dsDNA and are then integrated into the host genome where it becomes

-
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a provirus and replicates itself in parallel with the host cell using host cell machinery
[140]. HIV encodes for 9 open reading frames (ORFs). The three largest are the
polyproteins Gag, Pol, and Env which are later proteolytically processed into individual
proteins that are common to every member of the retrovirus family. The gag polyprotein
is cleaved into 4 different proteins, the matrix, the capsid, the nucleocapsid, and P6 which
eventually make up the structural components of the virus [68], The Pol polyprotein is
cleaved into the protease, reverse transcriptase, and integrase which provide enzymatic
functions which are necessary for the HIV lifecycle and are packaged within the mature
vims [69], The Env polyprotein encodes for cell surface receptor gpl20 as well as
transmembrane protein gp41. These two proteins make up the outer envelope proteins of
HIV [67], HIV also encodes for 6 accessory proteins, 3 of which (Viral Protein R [vpr],
Virion Infectivity Factor [vif], and Negative Regulatory Factor [nef]) are packaged with
the vims [66], Trans-activator of Transcription (Tat) and Regulator of Virion Expression
(rev) are necessary for gene regulatory functions and Viral Protein U (vpu) assists in
vims assembly; these proteins make up the remaining accessory proteins. In total, HIV is
made up of 15 proteins and two copies of (+) ssRNA genome (Fig. i).
1.42 HIV life cycle
Viral entry and uncoating
HIV infection occurs when the envelope protein gpl20 binds to the CD4 receptor found
on CD4+ T cells. Mucosal sites, such as the genital mucosa, have a large CD4+ T cell
population and act as a major site for viral infection. After gpl20 binds to the CD4
receptor, a conformational change occurs to allow for additional binding to the cellular
co-receptor CXCR4 [65]. HIV strains which target CD4 T cells predominately are
-
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termed T cell line tropic. Some HIV strains have shown different cell tropism and infect
macrophages predominantly. These macrophage tropic viruses also bind to CD4 but use
the co-receptor CCR5 as a co-receptor for entry [73]. Once adherence to the cell is
established, gp41 on the HIV envelope is exposed and also reaffirms adherence on the
cellular membrane. Gp41 also aids in bringing HIV and the cell in close contact to
promote the fusion of the viral and cellular envelopes [70]. This facilitates the release of
the viral core, or capsid, into the cytoplasm along with a number of packaged viral
proteins which are necessary for subsequent steps of viral replication (nucleocapsid,
reverse transcriptase, integrase, and vpr). Within one hour of envelope fusion, the capsid
is degraded or “uncoated” and the ssRNA genome is released into the cytoplasm and is
then reverse transcribed by the viral protein, reverse transcriptase [71,72], Although the
mechanism of capsid uncoating is not well characterized, it has been thought that the
degradation of the capsid is mediated by phosphorylation events in the cytoplasm [74,75].
It has been hypothesized that the catalytic domain of cellular cAMP, the C-PKA subunit,
can target capsid proteins and phosphorylate them to destabilize the structure and release
of HIV genomic RNA [74],
Reverse transcription
After the release of the viral genome and viral enzymes into the cytoplasm, the
reverse transcription complex is formed. This complex is made up of the viral reverse
transcriptase enzyme (RT), genomic RNA or viral RNA (vRNA) (flanked on each end by
short direct repeats known as, R), and a cellular transfer RNA (tRNA)- tRNA3 Lys [76].
This complex is required for the conversion of vRNA into DNA so that it may be
incorporated into the host genome. tRNA 3 Lys acts as a primer and binds to vRNA [76].
-
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This initiates the binding, initiation, and elongation by reverse transcriptase reading the
template in a 3’ to 5’ direction and generating the DNA in a 5’ to 3’ direction. This leads
to generation of a negative sense (-) DNA copy hybridized to vRNA [76]. In addition to
its polymerase activity, RT also contains RNase H which selectively degrades RNA when
it is part of an RNA-DNA hybrid. This degrades the parental RNA strand that is
complexed with the (-) DNA and exposes the ssDNA with the exception of a small
fragment of vRNA which is still bound to the (-) DNA. This small fraction of vRNA acts
as a primer for the synthesis of the (+) DNA strand. Synthesis of the second strand is in
the 5’ to 3’ and subsequently creates cDNA from the vRNA genome [76].
Nuclear Entry and Integration
Effective replication of HIV requires the active transport of generated cDNA from
the cytoplasm into the nucleus and integration into the host genome without the
breakdown of the nuclear envelope. Transport of HIV across the nuclear membrane
requires three proteins, matrix, integrase (IN), and vpr, which associate with viral cDNA
and form the pre-integration complex. Both IN and MA proteins contain nuclear
localization signals which are important for the direction of the pre-integration complex
into the nucleus. It is thought that the key regulator of the pre-integration complex is vpr
which binds to the nuclear transport molecule importin a. This interaction has been
shown to increase the affinity of importin a for the nuclear localization signals of both the
matrix and IN. This leads to the heterodimerization of importin a with importin P and
allows for the docking and transport of the entire pre-integration complex through the
nuclear pore and into the nucleus [80].
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Integration of viral cDNA into the host genome requires the viral enzyme IN. IN
has two major catalytic functions, endonucleic cleavage of 3’OH groups of viral DNA
and strand transfer reaction allowing for the transfer and incorporation of viral DNA into
host DNA [81-86]. At each end of the viral DNA strand, an IN dimer binds and cleaves
3’OH groups, also known as 3’ processing, resulting in the removal of a dinucleotide
from each end of the viral DNA [87], The two IN dimers then come together to form an
IN tetramer and also bring the two ends of viral DNA together [88], As IN performs its
catalytic activity, IN simultaneously binds the viral DNA as well as 26 base pairs (bp) of
target host DNA. The resulting cleaved viral DNA is then integrated into the host
genome with 5bp between the two points of insertion in a process called strand transfer
[87-92].
Transcription
Transcriptional initiation of HIV replication requires the binding of a number of
cellular transcription factors and enzymes to the promoter region of the HIV genome
located at the U3 region of the long terminal repeat (LTR). The HIV promoter contains
two NF-kB and three Spl binding sites for their respective transcription factors as well as
an initiator site called, start-site region [103,104]. These sites are located upstream of the
RNA polymerase II (RNAPII) TATA box region also located on the HIV promoter. The
TATA box is recognized by the TATA binding protein which also binds 8-12 additional
TATA associated factors [105,106]. Once all transcription factors and associated TATA
associated factors are bound, RNAPII binds to TATA binding protein and is able to
initiate transcription. However, only low levels of short vRNA transcripts are produced
[107-109],
-
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Highly efficient transcription of the HIV provirus requires the association of the
viral protein tat to the promoter. This is only possible through the expression of TAR
RNA. All HIV RNA transcripts express a TAR element (Trans-activation Response
Element), a stem loop secondary structure found at the 5’ end of vRNA, and serves as a
binding site for tat [93,94], The low levels of short RNA transcripts generated initially
act as an attractant for tat binding. Tat-TAR interactions are stabilized by the recruitment
of cyclin T l, leading to higher affinity binding of tat-TAR [95]. The cellular protein
Cdk9 also binds to this complex and together with cyclin T l constitutes the positive
transcription elongation factor b (p-TEFb) [96]. P-TEFb is hyperphosphorylates the
carboxyl terminal domain of RNA polymerasell and enhances its function which
generates elongated RNA transcripts [96-99]. Acetylation of tat also helps to generate
elongated transcripts by binding the PCAF protein which causes the dissociation of tat-pTEFb and PCAF from TAR and RNAPII [100-102],
Nuclear Export o f Viral RNA and Translation
Full length RNA transcripts function both as genomic RNA as well as mRNA for
the expression of gag and pol genes. However, expression of genes downstream from
gag and pol require extensive splicing of the primary transcript. With the exception of a
few viral mRNA (nef, tat, and Rev) most viral transcripts require the viral protein Rev to
be shuttled out of the nucleus [141,142], After its translation in the cytoplasm, Rev
relocalizes to the nucleus through a nuclear localization signal, an arginine rich motif on
Rev which binds the cellular nuclear import factor Importin P [143]. In the nucleus,
multimers of Rev bind to a stem loop structure located in the Env gene called the Rev
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response element (RRE) through the same arginine rich motif and masks the nuclear
localization signal [144,145].
The export of Rev-RRE complexes require a nuclear export signal which is a
leucine rich sequence found on the C-terminus of Rev [146]. This allows Rev-RRE to
hijack a cellular pathway for RNA export [146]. The cellular protein, Crm l, binds RevRRE and localizes to the nuclear pore complex and interacts with a number of nuclear
proteins including Ran, a GTPase that is involved in RNA export to the cytoplasm [147149, 138]. RNA export by Ran requires an energy gradient created by an asymmetric
distribution of Ran-GTP and Ran-GDP across the nuclear membrane (high levels of
nuclear Ran-GTP in the nucleus, low levels in the cytoplasm) [138]. High levels of RanGTP in the nucleus favour binding of Ran-GTP with nuclear export signal containing
proteins such as Crml-Rev-RRE which is very stable [148,150]. Once bound to RanGTP, the Crml-Rev-RRE complex is able to be transported out of the nucleus into the
cytoplasm mediated by the GTP disparity energy gradient [150]. Once in the cytoplasm
RanBPl binds Ran-GTP to catalyze the disassociation of the bound components (CrmlRev-RRE). This allows Rev to re-enter the nucleus via the mechanism described above
and continuously shuttle vRNA back into the cytoplasm [150] (Fig. ii). Once in the
cytoplasm, RNA transcripts are translated through two different mechanisms: Either by
the classical 5’ cap dependent translation initiation (less common), or through internal
ribosomal entry sites (IRES) (more common) [151]. The classical 5’cap mechanism is
maintained by all cellular proteins as well as HIV proteins which code for gag and pol
[152-154], In this mechanism, the 5’ cap on the RNA transcript is recognized by the
cellular factor eIF4E and leads to the unwinding of the secondary RNA structures by the
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eIF4A helicase. eIF4E also acts as a scaffold for the binding of eIF4G which coordinates
the binding of 40S ribosome and the initiation of translation [155, 156]. IRES mediated
translation initiation allows for direct recruitment of an initiation complex (either direct
recruitment of the 40S ribosomal subunit, an IRES transacting factor, or by other
initiation factors) near or at the AUG start codon [157]. Although there are no consensus
sequences which are characteristic of IRESs, these sites are often structurally similar in
that they contain a long and structured LTR and several AUG triplets [158].
Assembly
Incorporation of viral proteins into a maturing virion requires their transport to the
cell membrane. Gag polyprotein shuttling to the cell membrane and virus formation
requires 3 domains: 1) the membrane domain which is post-translationally myristoylated
at the N-terminus of the matrix for interaction with the cell membrane. 2) The Interaction
domain, which is found at the N-terminus of the nucleocapsid, promotes gag-gag
interactions at the membrane and leads to oligomerization at the plasma membrane (PM).
3) The PTAP motif or the late domain found on the N-terminus of p6 is necessary for the
last stages of viral budding [159-162],
The membrane domain, along with highly basic residues, comprise a membrane
targeting motif which interacts with acidic phospholipids on the PM [110]. The myristic
acid addition to the matrix also allows gag to target lipid rafts on the PM.
Phosphatidylinositides (PI) are a class of phosphorylated fatty acids which are implicated
in cellular trafficking to various organelles. The Pis PI(4)P, PI(4,5)P2, and PI(3,4,5)P3
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Fig. ii Rev shuttling. Once translated in the nucleus, Rev binds importin p and Ran-GDP to
re-enter the nucleus. Once RCC1 performs GEF activity on Ran-GDP converting it to RanGTP, rev and importin p dissociate. Rev is then able to bind RRE of HIV mRNA, CRM1
nuclear exporter, and Ran-GTP. With increased Ran-GTP in the nucleus, rev uses the GTP
energy gradient generated across the nuclear membrane to export HIV mRNA into the
cytoplasm. Hydrolyzation of Ran-GTP in the cytoplasm by RanGAP and RanBpl leads to
the dissociation of the Rev complex and HIV mRNA is able to be translated.
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are able to target to the PM and thus proteins that interact with these Pis are also
trafficked to the PM. In particular PI(4,5)P2 is a major PI for PM trafficking and
regulates a variety of membrane events such as endocytosis, exocytosis, synaptic vesicle
trafficking etc. Gag trafficking to the PM is thought to exploit PI(4,5)P2 to get to the PM.
In particular PI(4,5)P2-gag preferentially targets lipid rafts on the PM [178]. Lipid rafts
preferentially interact and incorporate saturated fatty acids. The myristic acid
modification of gag is a highly saturated fatty acid and is therefore incorporated into the
raft. As gag is continually transferred to the membrane, gag-gag interactions are formed
through the Interaction domains of the gag polyproteins [161].
Pol exists only with the coexpression of gag in a large gag-pol polyprotein.
However, gag-pol requires the assistance of the gag polyprotein to shuttle to the PM.
Gag and gag-pol polyproteins interact in the cytoplasm through the major homology
region in the capsid region. Gag-pol therefore hitchhikes to the PM with the assistance
by binding directly to myristoylated gag and targeting to the cell membrane [179],
Interestingly, gag-pol is not the only viral protein which uses gag to assist in membrane
trafficking. Vpr directly binds the p6 region of gag to promote its incorporation into the
maturing virion [180,181]. In addition, HIV genomic RNA contains 4 stem loop
structures (SL1-4) known as a psi-site (\|/) which is recognized by the nucleocapsid of gag
polyprotein and allows for packaging of genomic RNA into the virion. SL2 and SL3 are
the main binding determinants of y and interact with the nucleocapsid through zinc finger
binding [182-184], SL1 is necessary for genomic RNA dimerization whereas SL4 is
necessary for stabilization of the tertiary structure of \\i [185,186].
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To form the mature structural components, gag and gag-pol precursor
polyproteins must be cleaved by the viral protease (PR) located in the pol region of gagpol. Activation of the protease occurs when dimerization of the PR domains of gag-pol
leading to intramolecular cleavages (ie. The PR domains of each gag-pol cleave different
processing sites within the gag-pol precursors that make up the dimer) [111, 112].
Through autocatalytic processing, the PR cuts itself out of the polyprotein by cleaving
peptide bonds at either ends of its sequence [187,188]. After being released, the PR
continues to cut peptide bonds within the gag-pol polyprotein to release the RT, IN, and
the structural components of the virus (matrix, capsid, nucleocapsid, p6) [189].
The transmembrane envelope glycoprotein gpl60 is the precursor protein of the
proteolytically cleaved glycoproteins gpl20 and gp41. Gpl60 oligomerizes in the
endoplasmic reticulum as a trimer (predominantly) and is then transported to the cell
membrane via the secretory pathway. During its trafficking through the golgi, it is
cleaved by the host protease, furin to produce gpl20 and gp41 which form a fusion
complex together through non-covalent interactions [116-118]. The mechanism by which
gp41/gpl20 is incorporated into the maturing virus is not fully understood, however it has
been suggested that the cytoplasmic tail of gp41 recognizes the matrix domain of gag and
allows for its incorporation into virions [114,115].
Budding and Maturation
The late domain on p6 of gag contains a PTAP motif that is recognized by the
cellular factor TSG101 which also binds to another PTAP domain of AIP1 and a number
of additional proteins to make up the ESCRT-I complex [190,191]. The AIP1 of the
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ESCRT-I complex interacts with CHMP4 proteins which oligomerize at the PM and
make up the ESCRT-III complex [191,192], ESCRT-III proteins interact with an ATPase,
VPS4. The N-terminus of VPS4 is responsible for the binding of ESCRT-III complex
whereas the C-terminus contains a (3-domain which interacts with the protein LIP5 [194],
VPS4 functions as a hexameric ring in which the N-termini are central to the ring and the
P-domains are on the perimeter. When two VPS4 hexameric rings are stacked, they
attain full enzymatic function and disassemble the ESCRT-III complex which provides
energy for membrane fission [193], However, the precise mechanistic details remain to
be elucidated.
Maturation of the viral particle occurs when gag and gag-pol are cleaved to form
their mature structural and enzymatic forms. Cleavage of these polyproteins is performed
by the viral protease but it is unclear whether this occurs during the budding process or
whether it happens after budding in the immature virion [189].
1.5 Interferon Response
Interferon (IFN) is an indispensible mechanism of defence against viral infection
in vertebrates. Mice that lack a subunit of the IFN receptor (IFNR) quickly succumb to
viral infections despite having a normal adaptive immune system [119]. Two pathways
exist that lead to the upregulation of IFN in response to viral infection: the classical
pathway and toll-like receptor (TLR) pathway. The classical pathway is used by
fibroblasts, hepatocytes, and conventional dendritic cells which detect viral infection
through the use of cytoplasmic receptors that recognize viral components and upregulate
the transcription factors IRF3 and NF-kB to activate IFN-[3 gene expression [124], For
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example, the dsRNA sensors MDA5 and RIG-I are expressed ubiquitously across most
tissues and are upregulated in response to IFN. Subsequently, upon sensing dsRNA,
RIG-I and MDA5 amplify the production of IFN [120, 123]. The TLR mediated pathway
is mediated by plasmacytoid dendritic cells which are strong producers of IFNa. These
are strong sensors of DNA viruses and RNA viruses through the use of TLRs found in
endosomes. HIV infection is recognized by cells through the sensation of intracellular
ssRNA by TLR 7 and 8 [121, 125]. Activation of these TLRs causes the formation of a
complex between their adaptor molecule, MyD88 and TRAF6 and IRF7. IRF7 is
phosphorylated by IRAK-1 which leads to its activation and expression of IFNa [122]
(Fig. iii a). IFNs are cytokines which modulate cell growth, activate other antiviral
cytokines, and promote an antiviral response. IFN ot/(3 are sensed by the IFNR which is
comprised of two major subunits, Interferon alpha receptor subunit 1 (IFNAR1) and
IFNAR2 [126,127]. Binding of type I IFNs causes the two subunits to associate which
leads to the phosphorylation, dissociation, and activation of Tyk2 and JA Klat the
cytoplasmic domain of IFNR. This allows for binding of STAT1 and STAT2 on
IFNAR1 on which they are phosphorylated and subsequently translocate into the nucleus
where they associate with the DNA binding protein p48 [128, 129]. This heterotrimer is
known as ISGF3 which bind ISRE (IFN stimulated response element) of the IFN a /(3
genes. This leads to the upregulation of over 300 IFN stimulated genes such as antiviral
restriction factors (Fig. iii b).
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Fig. iii Interferon signalling. A) recognition of ssRNA by TLR7 or 8 causes a
signalling cascade that activates transcription factors IRF7 and NF-kB and lead to the
upregulation of type 1 IFN cytokines. B) Interferon a/p are recognized by type 1
interferon receptor composed of INFAR1/INFAR2. This causes the phosphorylation
and dissociation of Tyk2 and Jakl and association of STAT1 and STAT2. These are
phosphorylated and translocate to the nucleus where they bind to the DNA binding
protein p48. This leads to the upregulation of a number of antiviral restriction factors
including Herc5 and ISG15.
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1.51 Restriction Factors
In response to a viral infection and IFN stimulation, host cells upregulate a
number of proteins to control viral replication known as restriction factors. In response to
HIV, PKR is able to restrict translation. Again after binding the TAR element, PKR
phosphorylâtes the protein eIF2a which is normally involved in the transfer of met-tRNA
to the 40S ribosome for translation. Phosphorylation of eIF2a restricts its ability to
transfer the start codon to translating proteins thus restricting all protein production [163165]. OASl/RNaseL also inhibits translation of HIV by recognizing dsTAR RNA [167].
Once activated OAS1 forms a tetramer which breaks down ATP into 2-5 oligoadenylates
which are strong activators of RNaseL [167,168]. The RNaseL enzyme degrades all
ssRNA in the cell including mRNA thereby restricting all translation including viral
translation [166-168],
Other viral restriction factors include the TRIM family of proteins; a number of
which have been shown to be able to restrict HIV. TRIM5a is able to prevent HIV viral
uncoating in the cytoplasm by binding to the viral core and preventing the degradation of
the capsid thus inhibiting the unpackaging of the RNA genome [169], TRIM22 has been
shown to restrict HIV by inhibiting the release of gag polyprotein (which is able to
release from cells without any other viral proteins) and preventing the accumulation of
gag at the cell membrane though the precise mechanistic details behind TRIM22
restriction of HIV need to be elucidated [170,171].
1.52 Interferon Stimulated Gene 15 (1SG15)
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Interferon stimulated gene 15 (ISG15) was the first ubiquitin like modifier
discovered and is strongly upregulated in response to type I interferon production and
viral infection in vertebrate species [172]. Similarly to ubiquitin, ISG15 is a
posttranslational modifier of proteins that requires an E3 ligase, an E l enzyme, UbelL
and an E2 enzyme, UbcH8. The E l enzyme, U belL recognizes ISG15 and passes it to
the E2 enzyme through a transthiolation reaction. When ISG15 is bound to the E2,
UbcH8, they bind to the E3 ligase which also binds the protein substrate and facilitates
ISG15 conjugation to the substrate [175-177].

ISG15 contains two ubiquitin-like

domains at the N-terminus and C-terminus which are connected by a central hinge region
made up of 5 beta sheets and 1 alpha helix (Fig. iv). The C-terminus is predicted to be
the main point of interaction with its E l enzyme UbelL, specifically through the residues
K90 (lysine), W123 (tryptophan), and F149 (phenylalanine) [54], The C-terminus also is
required for the transfer of ISG15 from UbeEL to the E2 enzyme, UbcH8, which is
mediated by transthiolation reactions. The N-terminus however is predicted to be
responsible for the E3 mediated transfer from the E2 enzyme, UbcH8, to the target
substrates [55], There are currently two well known E3s for ISG15 conjugation, the main
ISG15 conjugator being the HECT domain and RCC-1 like domain containing protein 5
(Herc5) and Estrogen-responsive finger protein (EFP) [195,196]. As a response to IFN
stimulation and defence against viral protein expression, Herc5 has been shown to
associate with the 60S subunit of polyribosomes (groups of ribosomes bound to mRNA)
and broadly ISGylates newly synthesized proteins in an attempt to inhibit vims assembly.
Although ISGylation of a broad range of newly synthesized proteins is relatively
inefficient, it is believed that this is beneficial to the host cell to minimize excessive
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Fig. iv The crystal structure of ISG15. Two ubiquitin -like domains are joined at a
central hinge region. C-terminus is necessary for binding the El enzyme, U belL and
the transfer to E2 enzyme, UbcH8. The N-terminus is required for E2 transfer to the
E3 ligase and target substrate [54],
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damage to host proteins. In addition, structural proteins of viruses often require very
precise gefometric configurations to form infectious particles; ISGylation of even a small
portion of these viral proteins may lead to the restriction of virus production [62],
ISG15 is able to act as a restriction factor against HIV budding by interfering with
the interaction of TSG101 with the p6 domain of gag although neither protein is directly
modified with ISG15 [173]. ISG15 is also able to interfere with Vps4 recruitment to the
ESCRT-III complex. Although this mechanism is not fully elucidated, it is believed that
ISG15 binds to components of ESCRT-III and prevents Vps4 recognition of the complex.
The result of such restriction leads to the formation of “lollipop” structures on the surface
of infected cells where virus is unable to be pinched off and released from the cell [174],
It is unclear what the physiological significance of ISG15 conjugation is.
However, experiments determining ISGylatable proteins have been performed to help
elucidate its relevance. The proteins JAK1 and STAT1 were among the first proteins to
be discovered which can be ISGylated. Both JAK1 and STAT1 are key components of
the interferon activating pathway. It is possible that ISGylation of these proteins in the
interferon signal transduction pathway is a method of regulating the expression of
interferon either positively or negatively [56,57]. Since ISG15 is upregulated within the
first 24 hours in response to cellular stressors and pathogens, it is believed that ISG15 is
involved predominately in innate immune responses. However, it has also been shown to
be involved in a diverse range of cellular processes such as protein trafficking and
cytoskeleton organization [58].
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Studies show that ISG15 can also target and conjugate to the Influenza A NS1
protein after type I interferon treatment. The NS1 protein of Influenza A is able to
interfere with host mRNA processing and is also able to shut off a number of cellular
defences against virus infection such as OAS1 ISGylation of the NS1 protein has shown a
robust ability to inhibit vims replication. Krug and colleagues found that K41 is the
predominant residue for ISG15 conjugation of NS1. This region of NS1 is responsible
for binding dsRNA in order to block the activation of a number of different antiviral
proteins which are activated by the recognition of dsRNA, a pathogen associated
molecular pattern. It is thought that ISG15 conjugation in this region of NS1 would
block NS1 from binding to dsRNA and allow for greater antiviral activity within the cell
[63],
Hepatitis C Vims (HCV) replication is also strongly diminished with interferon
induction and ISG15 overexpression. The NS5A protein of HCV is ISGylated at K379 of
the C-terminal region which subsequently leads to protein instability. The mechanism of
restriction is again unclear. Experiments with NS5A conjugated with ISG15 show that
the NS5A protein is not being degraded by the 26S proteasome. However, it was shown
that NS5A was both ubiquitinated and ISGylated and that these two in parallel were
involved in altering the proteins’ stability [64],
Interestingly, ISG15 also exists as a soluble protein which can be excreted into
extracellular space as an immunomodulatory cytokine upon stimulation of type I
interferons. Secretion of ISG15 as a cytokine was shown to enhance NK cell and
lymphocyte proliferation and killing. ISG15 is secreted by non-hematopoetic cells and
predominantly secreted by peripheral blood mononuclear cells (PBMCs). ISG15 may be
- 30-

acting as a signal of cell stress or cell damage. It is possible that ISG15 found in
extracellular fluid may be the product of cell death and is behaving as a danger associated
molecular pattern rather than a secretory product [61].
The over expression of the ISG15 E l protein, UbelL, has been shown to help
control the development of lung cancer by inhibiting the growth of bronchial epithelial
cells and lung cancer cells. This may be due to U belL promoting ISGylation of cyclin
D1 and causing its destabilization and abrogates cell cycle [59].
However ISG15 has also been reported to be an oncogenic factor. Many different
tumors and tumor cell lines have displayed ISG15 disregulation and elevated levels of
ISG15. This may be due to constitutively activated NF-kB found in many tumor cells
which in turn continuously produces interferon and subsequently ISG15. In tumor cells
where ISG15 is constantly elevated, polyubiquitination and degradation is strongly
diminished however the mechanism by which ISG15 impairs ubiquitin conjugation
remains to be elucidated. It is possible that ISG15 competes for the same lysine residues
as ubiquitin on many different target substrates or that certain E l, E2s, and/or E3s that are
common between ISG15 and ubiquitin are being sequestered or degraded by ISG15 [60],
Oddly, many of ISG15’s antiviral activities have been not been examined in the
presence of its main conjugator, Herc5. Thus studying the effect of Herc5 in the context
of a variety of viral infections is very important for determining whether Herc5 is also
able to act as a potent viral restriction factor.
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1.6 HECT domain and RCCl-like domain containing protein (Here) Family
The Here family of proteins are made up of 6 members that possess a ubiquitin
HECT domain (described in section 1.2) as well as an RLD [197,198] (Fig. v). The RLD
structurally resembles the protein RCC1. Both the RCC1 and the RLD of Here proteins
have a 7 bladed (3-propeller configuration where each blade is made up of 4 (3-sheets (Fig.
vi) [199,200]. The RCC1 protein interacts with Ran in the nucleus to catalyze the
conversion of Ran-GDP to Ran-GTP as a guanine nucleotide exchange factor (GEF).
The GTPase function of RCC1 is necessary for the generation of a GTP energy gradient
in the nucleus for the export of mRNA to the cytoplasm (the same pathway that is
hijacked by rev) [201-203]. The activity of RCC1 has also been implicated in nuclear
envelope assembly, mitotic spindle formation, and cell cycle regulation [204]. RCC1
activation depends on its binding to nuclear chromatin particularly at histones 2A and 2B.
Thus, RCC1 is able to interact with Ran on one face of the |3-propeller while it tethers to
nuclear chromatin on the other [200], Of the RLD containing Here proteins, H erd has
displayed GEF activity in its RLD1 whereas the RLD domain of Herc3 displays none. It
remains to be determined whether the other members of the Here family maintain an
RCCl-like GEF function [205].
The Here family is separated into two subgroups based on their size and domain
architecture. Here 1 and Herc2 belong to the large Here family where each is roughly
530kDa. Interestingly, these two Here proteins also contain multiple RLDs, H erd with
two RLDs and Herc2 with three [206], Although not much is known about these proteins,
it is thought that H e rd may have oncogenic properties as it is over expressed in a number
of tumor cell lines. It is also possible that H e rd is involved in membrane trafficking to
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the golgi [205], Hercs 3-6 belong to the small Here family whose sizes are
approximately 120kDa [206]. Phylogenetic studies on the Here family suggest that
Herc4 may be the most ancient of the proteins from which all other Hercs derived as it is
found in the nematode genome [198]. From such studies, Herc5 seems to be the newest
addition to the Here family [198].
1.61 Herc5
Herc5 is a type 1 interferon induced protein comprised of three major domains,
the RLD, a spacer region, and an E3 ligase HECT domain. Currently, the HECT domain
is the most well characterized region of Herc5 as it has been identified as the catalytic
domain for ISG15 conjugation. Herc5 functions in conjunction with the El enzyme
U belL and the E2 enzyme UbcH8 to conjugate ISG15 to target substrates [207], These
proteins are upregulated by type 1 interferons (Herc5 is upregulated 5 fold) which
suggests the pathway may play an important role in innate immunity [208]. This activity
has been described largely in terms of antimicrobial activity even though the
physiological relevance of ISG15 conjugation has yet to be determined in this context. A
cysteine residue at position 994 in the HECT domain is crucial to Herc5’s ability to
conjugate ISG15 to targets [208]. It has been shown that ISG15 conjugation at the RNA
binding domain Influenza A Virus NS1 by Herc5 is able to attenuate virus propagation
and virulence by inhibiting the interaction with Importin a and blocking nuclear import of
the NS1 protein [209,210, 216]. Although Herc5 has not been directly identified in a
number of antiviral activities, ISGylation has been shown to restrict Sindbis virus, Herpes
simplex 1, HIV-1, and Ebola. In addition, Herc5 ISGylation has been shown to enhance
the production of type 1 interferons by ISGylating interferon regulatory factor 3 (IRF3)
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Fig. v Here family of proteins is divided into two groups, the large and small Hercs. Both
H e rd and Herc2 belong to the large family of Here proteins roughly 530kDa and contain
multiple RLD domains. Herc3-6 all belong to the small Here family and are roughly 120kDa
[222],
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RCC1

Herc5 RLD

Fit

Fig vi. Herc5 RLD vs. RCC1- RCC1 and Herc5 RLD both contain 7 bladed propellers
made up of 4 (3-sheets. Although the amino acid sequences are only slightly homologous,
the structural homology is almost identical as depicted in the Fit panel in which both RCC1
and Herc5RLD are overlapped. (Courtesy of Stephen Barr)

-35-

and sustaining its function [177], This suggests Herc5 may have broader antiviral
activities than it is accredited for and thus act as a potent and versatile viral restriction
factor.
The spacer domain of Herc5 shows no homology to any known protein. However,
through predictive modelling, it is likely to be abundant in alpha helices similarly to
coiled coil domains. Coiled coil domains are important to many intermolecular
interactions including the formation of protein oligomers [212]. For example, gp41 of
HIV requires coiled coil interactions to adhere to the cell membrane [213]. The
ISGylating E3 ligase EFP contains a coiled coil domain which has been shown to be
important for autoISGylation and the interaction with its substrates [214]. It is possible
that the spacer region of Herc5 acts in a similar manner as EFP and acts as a binding
domain for Herc5 substrates or as a location for autoISGylation however further
characterisation of the protein is required to determine the functional role of this domain.
The RLD of Herc5 shares roughly 35% sequence homology with RCC1 however
predictive modelling of the Herc5 RLD shows almost complete structural identity with
RCC1 (Fig. vi). This raises the question whether the RLD of Herc5 has similar functional
behaviour as RCC1 as a GEF. Like RCC1, Herc5 has been implicated in the regulation
of cell cycle. Herc5 was shown to interact with the cyclin E-Cdk2 kinase which is
indispensible for the transition of G1 to S phase. Herc5 is also highly expressed when the
tumor suppressor proteins Rb and p53 are inhibited [215], It is possible that Cyclin ECdk2 is recognized by the RLD and ISGylated by the HECT domain which stabilizes or
degrades the complex to regulate cell cycle progression.
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As mentioned under the HECT E3 ligase section (appendix), the N-termini of E3
ligases predominately function as the binding domains for target substrates [10-12],
Therefore, it is possible the RLD may also act as the binding domain for Herc5 substrates
Mutational studies in which the RLD of Herc5 has been removed, ISGylation was shown
to be drastically reduced but not completely abolished [208], In addition, Herc5 binding
to NS 1A protein is eliminated when the RLD is removed [216],
ISG15 has been implicated in many antiviral activities, including the restriction of
HIV-1 at the late stages of virus release. However, many of its antiviral properties have
not been investigated in the context of its main E3 conjugating ligase, Herc5. Thus far,
Herc5 has only been directly implicated in antiviral activity through the restriction of
both Influenza A and B and is also upregulated during the course of Hepatitis C infection
[209,210,216,219], However, it is also upregulated 4 fold in the presence of type 1
interferons and positively regulates their expression by modifying interferon regulatory
factor 3 (IRF3) with ISG15 [211], Herc5 also broadly ISGylates newly synthesized
proteins upon type 1 interferon signalling [62], The potency of ISG15 as a viral
restriction factor and the implications of Herc5 in a variety of antiviral activities strongly
suggest that Herc5 may in fact have greater potential for restricting viral replication than
what is currently understood. Further investigation into the antiviral properties of Herc5
as a restriction factor must be conducted to better understand the physiological relevance
of Herc5 during viral infection in hopes of extrapolating its activity for novel antiviral
therapies.
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1.7 Preliminary data
Our lab has shown that Herc5 mediated ISGylation of the HIV-1 gag structural
protein is sufficient to restrict the release of virus-like particles (gag polyprotein release)
from U 20S cells. The C994A Herc5 mutant that lacks E3 ligase activity is unable to
restrict gag release. Herc5 transfected cells co-transfected with Ubp43, a delSGylating
enzyme, are also unable to restrict gag release. This suggests that ISGylating activity of
Herc5’s HECT E3 ligase domain is responsible for inhibiting gag budding from cells (Fig.
vii).
When cells are infected with replication competent HIV in the presence of Herc5,
there is restriction of HIV-1 release from the cell as well as restriction of gag protein
production in the cell. When C994A Herc5 is transfected into HIV infected cells, there is
still restriction of gag production in the cell and virus release (Fig. viii). This indicates
that the E3 ligase activity of Herc5 is not absolutely necessary for virus restriction and
that there are two mechanisms by which Herc5 can restrict viral replication - although it
is unclear what the second mechanism is. Therefore, characterizations of the RLD and
spacer regions are required to understand the second mechanism of HIV restriction.
Quantification of intracellular gag mRNA in cells infected with HIV-1 indicates
that in the presence of Herc5 there is a build up of gag mRNA that is not being translated
into protein in comparison to the negative control (3.5x more gag mRNA) (Fig. ix). It is
possible that mRNA is not being translated because there is a defect in mRNA shuttling
to the cytoplasm.
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Fig. vii HERC5 ISGylation leads to gag polyprotein restriction in U 20S cells. A) gag
transfected into U20S cells in the presence of Herc5, C994A, or negative control. Gag virus
like particle release was measured by western blot detection of gag polyprotein using gag
antibody. B) Western blot of gag release in Herc5 transfected cells and ISG15 conjugation
system in the presence or absence of de-ubiquitinating protein Ubp43. (Courtesy of Matt
Woods; Woods, M., et al., 2011. Unpublished)
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Fig. viii Herc5 restriction of HIV-1. pGL3, WT Herc5, or C994A, was co-transfected with
replication competent HIV-1 (R9) in U20S cells. Herc5 and C994A are able to restrict the
release of virus into cell supernatant. Herc5 and C994A are also shown to restrict gag
polyprotein production in the cell pellet in the presence of R9. (Courtesy of Matt Woods;
Woods, M., et al., 2011. Unpublished)
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Fig. ix qRTPCR of gag mRNA in HIV-1 infected cells. qRTPCR of gag mRNA in HIV-1
infected U 20S cells co-transfected with Herc5 or pGL3. 3.5x fold increase in gag mRNA in the
presence of Herc5. (n=3) (Courtesy of Matt Woods; Woods, M., et al., 2011. Unpublished)
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1.8 Hypothesis and Aims
I hypothesized that the spacer and/or RLD domains of Herc5 were necessary for
Herc5 mediated HIV-1 restriction since elimination of HECT domain activity did not
abolish Herc5 restriction of HIV-1. I also hypothesized that the Spacer or RLD is
interrupting proper export of mRNA from the nucleus to the cytoplasm. To approach my
hypothesis the specific aims of the project were: 1) to generate domain deletions of the
RLD and spacer domain as well as individual bladed deletions of the RLD region of
Herc5, 2) To determine whether the RLD or spacer domains were required for HIV-1
restriction using the mutants generated in aim 1,3) to explore the effects of these deletion
on the physiology of the host cell.
Chapter 2: Materials and Methods
2.1 Plasmid Constructs
RLD mutants via digestion, ligation, transformation- the wild type Herc5
construct in CS2+ plasmid backbone was generously supplied by K. Chin at Genome
Institute of Singapore. This construct was used to subclone all mutants of Herc5 into the
pFLAG plasmid backbone. Various mutations of the Herc5 RLD were generated using
primers recognizing the sequences encoding each blade of the RLD creating increasingly
larger truncations of the domain. All forward primers included the Bglll restriction site
and all reverse primers included Xbal restriction sites. Primers and template were used in
PCR reactions to amplify the tmncated forms of Herc5 lacking blades of the RLD (Fig. x).
Primer sequences used for the generation of pFLAG RLD mutants can be found in
Supplementary Table 1. PCR conditions used to amplify the RLD truncations to be
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incorporated in pFLAG are found in Supplementary Table 2. PCR products were then
purified using spin column PCR purification (Invitrogen and BioBasic) and used in single
enzyme digests with both Bglll and Xbal using buffers3 and buffer 2 respectively (New
England Biolabs). Digests were done for 2 hours at 37°C and purified after each digest.
After digestion of pFLAG vector with Bglll and Xbal, digested DNA and vector were
ligated using T4 ligase (New England Biolabs) for 20 minutes at room temperature. The
product was then transformed into DH5a competent cells and grown on LB agar plates
containing ampicillin overnight (16 hours) at 37°C. Bacterial colonies grown were
screened for insert by extracting plasmid DNA with Purelink Quick Plasmid Miniprep
Kit (Invitrogen). Products were digested with a single enzyme (Xbal or Bglll), and run
on an ethidium bromide 1% agarose gel with a 1Kb ladder. Lanes with an appropriately
sized DNA product (insert + product= ~7.5Kb - 8 Kb) were sent for DNA sequencing for
additional sequence verification at Robarts Research Institute.
RLD mutants and spacer mutant created with modified site directed mutagenesis and
transformation- RLD deletion constructs and the spacer deletion mutant were made using
modified site directed mutagenesis and designed to be expressed in the CS2+ plasmid
vector. WT Herc5 in pCS2+ vector was generously provided by K. Chin at the Genome
Institute of Singapore, from which all RLD and spacer deletions were subcloned.
Primers were designed to recognize sequences directly before and after the region to be
deleted (Table i). pCS2+ plasmid map is included in Supplementary Figure 2. The
QuikChange® Lightning Site-Directed Mutagenesis Kit and its corresponding protocol
were used for the PCR amplification of the RLD and spacer mutants of Herc5 (Table ii).
After amplification, PCR products were digested with Dpnl enzyme (40 units per reaction)
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at 37°C for 5 minutes to digest methylated, supercoiled parental dsDNA and isolate
desired Herc5 mutants. Digested products were then transformed into XL-10 Gold
ultracompetent cells. 45ul of ultracompetent cells were added to 14ml round-bottom
tubes and supplemented with 2ul of P-mercaptoethanol mix (provided with cells). This
was incubated on ice for 2 minutes after which 3ul of Dpnl (60 units) digested PCR
amplified Herc5 mutated DNA was added to the cells. This mixture was incubated on ice
for 30 minutes and then heat pulsed at 42°C for 30 seconds. The reaction was then
placed back on ice for 2 minutes. 0.5ml of preheated (42°C) SOC media (0.5% Yeast
E xtract, 2% Tryptone, lOmM NaCl, 2.5mM KC1, lOmM MgCL, lOmM MgSCL, 20mM
Glucose) was then added to each tube and incubated at 37°C for 1 hour while shaking at
225rpm. 300ul of each reaction was plated on ampicillin agar plates and left at 37°C
overnight (>16 hours). Colonies obtained from incubated plates were then screened for
desired inserts (mutated Herc5 constructs). Colonies were picked and grown in 1.5ml of
LB broth supplemented with lOOuM of ampicillin overnight (>16 hours). Resulting
bacterial suspensions were pelleted and miniprepped using BioBasic™ EZ-10 spincolumn plasmid DNA minipreps kit to extract transformed plasmid. The resulting
product was then quantified using Implen nanophotometer to determine DNA
concentration. 300ng of product was loaded on a 1% Ethidium Bromide (EtBr) agarose
gel and run at 120 volts for 45 minutes alongside a 1Kb DNA ladder. Products
corresponding to the approximate size of product and insert were sent to Robarts
Research Institute where they were sequenced verified. Confirmed mutants were then
maxiprepped with Qiagen® plasmid maxi kit and ready for transfection.
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Fig. x RLD mutant design. A) Mutations of the RLD were designed to delete sequentially
greater portions of the domain. 7 mutants of the RLD were originally intended, each deleting
one blade more of the RLD than the last. B) Primers recognizing the start of the different
RLD blades were designed and used for PCR amplification of the different Herc5 RLD gene
products. PCR products were run on a 1% agarose gel and visualized using ethidium bromide
staining. Al, Al-3, ARLD were successfully cloned into pFLAG; Al-2, Al-4, Al-5, Al-6 DNA
inserts were unable to be cloned into pFLAG. Primer sequences can be found in
Supplementary Table 1.
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Table i. Primers used for pCS2+ Herc5 RLD mutants and Spacer domain deletion.
Primers are made up of sequences before and after region to be deleted and omit the
sequence of the area being deleted. Bold segments bind to the region after the region
deleted (head), while the non bold sequences bind the region before the region to be
deleted (tail).

Deletion
ARLD

A1-2RLD

A1-5 RLD

Aspacer

Forward Primer Sequence
5 ’ GACATG GAG CGC CGC
AGC ATG ATT GCT GGA
GGG AAT CAA AGC ATT
TTG CTC TGG 3’
5 ’ GACATG GAG CGC CGC
AGC CAG GGA GCC GAA
CAC ATG CTG 3’
5 ’ GACATG GAG CGC CGC
AGC GAT GGG CTG CTG
TTT ACT TTC GGT GC 3’
5’ ATG ATT GCT GGA GGG
AGG CCC ACG TTT GAT
CTA ACA GTC AGA AGG 3’
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Reverse Primer Sequence
5’ GCT TTG ATT CCC TCC AGC
AAT CAT GCT GCG GCG CTC
CAT GTC GTC3’
5’ GTG TTC GGC TCC CTG GCT
GCG GCG CTC CAT GTC GT 3’
5’ AGT AAA CAG CAG CCC ATC
GCT GCG GCG CTC CAT GTC
GTC 3’
5’ GAC TGT TAG ATC CCC TCC
AGC AAT CAT TAT TAA CTC
CTT TTC TGA GG 3

Table ii. PCR conditions for pCS2+ Here mutants. A) Conditions for amplification of
pCS2+ Herc5 RLD mutants and Spacer deletion mutants B) Thermocycling conditions
required for amplification of RLD and Spacer mutants

5ul

lOx Reaction buffer

120ng

dsDNA template (pCS2+ Herc5)

lui

QuikChange® Lightning enzyme

125ng

Forward primer

125ng

Reverse primer

lui

dNTP mix

1.5ul

QuikSolution reagent

2.5ul (5%)

DMSO

Xul

ddH20

50ul

Total volume

B.
Temperature

Time

# of cycles

Initial Denature

95°C

2 minutes

lx

Denature

95°C

20 seconds

18x

Annealing

60°C

10 seconds

18x

Extension

68°C

4 minutes

18x

Final Extension

68°C

5 minutes

lx

-
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2.2 Cell culture, plasmids, and transfection
U 20S, HeLa, 293T and HOS cells were cultured at 37°C and 5% C 02 in Dulbecco's
modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS)
and 1 0 0 IU penicillin/ lOOug/ml streptomycin. Cells for all experiments were seeded in
either 6-well dishes containing 2ml of DMEM or in 12-well dishes (BD Biosciences)
containing 1ml of DMEM. Herc5 constructs were described previously.
2.21 Transfections
Lipofectamine transfection
Lipofectamine 2000 (Invitrogen) was used for single or dual plasmid transfection of
plasmids. A total of 2ug of DNA and 4ul of lipofectamine were transfected into 12-well
dishes of HeLa cells at 90% confluency and a total of 4ug of DNA and lOul of
lipofectamine were transfected into each 6-well 10cm well (BD Biosciences). Protocol
included in the kit was followed without modifications. Lipofectamine was used for all
confocal microscopy experiments and HIV release assay.
FuGene transfection
FuGene® HD (Roche) was used for single plasmid transfection of HeLa cells at 70%
confluency. 2ug of DNA and 4ul of FuGene were used for each 6-well, 10cm2 well.
Protocol included in the kit was followed without modifications. FuGene was used for
RTPCR transfection experiments for mRNA expression of Herc5 construct and
propidium iodide staining for cell cycle analysis
SuperFect Transfection
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SuperFect (Qiagen) was used for single plasmid transfection of HeLa cells at 90%
confluency. 2ug of DNA and lOul of SuperFect transfection reagent were used for each
6-well, 10cm2 well. Protocol included with the kit was followed without modifications.
SuperFect was used for growth comparison experiment between the different Herc5
construct transfected cells.
2.3 mRNA expression of protein constructs
6-well plates of U 20S were transfected with FuGene® at 70% confluency. Cells
were harvested after 24 hours and RNA extraction was performed using PureLink™
RNA Mini Kit (Invitrogen). RNA was then reverse transcribed using M-MLV Reverse
Transcriptase (Invitrogen). The protocol supplied with reverse transcriptase was not
altered. cDNA was then used to amplify various Herc5 mutants using PCR. lOul of
products were then run on a 1% agarose gel next to a 1Kb DNA ladder (New England
Biolabs) (Table iii).
2.4 HIV-1 release Assay (performed by Matthew Woods)
6-well plates of U 20S cells were co-transfected with replication competent HIV-1
(R9 plasmid) and one Herc5 construct using lipofectamine at 70% confluency. 1ml of cell
supernatant was collected 48 hours later and stacked on top of 300ul of 20% sucrose.
Supernatant was spun at 14000g for 2 hours to collect extracellular virus. Cell pellets
were also collected after 48 hours. Once the supernatant was collected, both cell pellet
and supernatants were lysed (separately) using RIPA lysis buffer and run on a 10% SDS
page gel. Detection of capsid protein and gag polyprotein were done using anti-p24
antibody. Mouse IRDye 680 secondary antibody (LiCOR) was used to illuminate
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primary antibody bound to p24 protein and rabbit IRDye 800 antibody (LiCOR) for actin
control.
2.5 Growth analysis of Herc5 construct transfected cells
6-well plates of HeLa cells were transfected at 90% confluency using SuperFect
transfection reagent (Qiagen) with one of the Herc5 constructs according to the
specifications outlined in the included protocol. Three hours after transfection, cells were
harvested and 250000 cells were seeded into each well of ten 12-well dishes (two dishes
were needed to count each day for growth comparison between constructs for a total of 4
days). For each Herc5 construct, 3 wells were seeded (done in triplicate) for each day the
experiment was to be carried out (a total of 12 wells were seeded for each construct).
Each day, 3 wells were counted using a hemocytometer for each construct and growth
was monitored over 4 days. Growth rates of cells transfected with the different Herc5
constructs were compared to the negative control transfected (pGL3) cells and
statistically analyzed using two-way ANOVA.
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Table iii. PCR conditions for RTPCR of Herc5 CS2+ mutants. A) Conditions used
for PCR reaction performed for RTPCR of Herc5 construct mRNA. B) Thermocycling
conditions needed for amplification of Herc5 construct cDNA

A.
5ul

lOx Pfu buffer

6ul

M gS04

lui

lOmM dNTPs

lui

Forward primer (fwd spacer primer)

lui

Reverse primer (herc5 reverse coding region primer RLD rev)

2.5ul

DMSO

lui

Pfu enzyme

7ul

cDNA template

25.5ul

Water

50ul

Total

B.
Temperature

Time

# of cycles

Initial Denature

95 °C

3 minutes

lx

Denature

95 °C

30 seconds

32x

Annealing

50.5°C

30 seconds

32x

Extension

72°C

4 minutes

32x

Final Extension

72°C

10 minutes

lx

-
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2.6 Confocal Microscopy
Hela cells were seeded in 6-well dishes and transfected using lipofectamine 2000
at 90% confluency. After 24 hours, cells were harvested with PBS EDTA and 3.5x10s
cells were transferred into 12-well dishes with 18mm coverslips and fresh media. 24
hours after, cells were washed with lxPBS /1%FBS twice and fixed with a fixing buffer
for 10 minutes (19ml lxPBS, 1ml Formaldehyde, 0.4g Sucrose). Cells were washed
twice again with lxPBS/l%FBS and then permeabilized with a permeabilization buffer
for lOminutes (19ml lxPBS, 1ml 10% NP40, 2g Sucrose). Cells were washed twice with
lxPBS/l% FBS then stained with primary antibody for rev or FLAG (Herc5) (1:1000) for
1 hour. Cells were washed using the lxPBS/l%FBS 6 times over 15 minutes and stained
with a secondary antibody for 1 hour (1:1000). Cells were washed again 6 times over 15
minutes and then mounted on to slides using VECTASHIELD® hard set™ mounting
medium with DAPI. Slides were then examined using a Zeiss LSM 510 META confocal
microscope mounted on an inverted Axiovert 200 motorized microscope. For statistical
analysis, 100 cells were counted for each different condition and were categorized
according to their nuclear morphology (either lobed or not lobed) or the Rev localization
(nucleolar, nuclear, nuclear boarder, cytoplasmic).
2.7 Propidium Iodide Staining for Cell Cycle analysis
U20S and 293T cells were transfected using FuGene® at 70% confluency.
24hours after transfection, cell cycle control cells were treated with hydroxyurea (ImM)
dissolved in water. 24 hours after drug treatment, cells were harvested with PBS/EDTA
and washed twice with PBS. Cells were resuspended in 0.5ml of PBS (single cell
suspension) and added to 4.5mls of ice cold 70% ethanol and kept on ice for 2 hours to
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allow for fixation. Cells were collected by centrifugation at 300xg for 5 minutes and
ethanol was decanted. Cells were then washed and resuspended in PBS then collected by
centrifugation at 200xg for 5 minutes. PBS was decanted and cells were suspended in
0.5ml of propidium iodide staining solution (10ml 0.1%Triton X-100, 0.5mg DNase free
RNaseA, 200ul of lmg/ml Propidium Iodide) and incubated at 37°C for 15 minutes.
Cells were then counted and analyzed using flow cytometry and interpreted using ModFit
LT™.
2.8 Statistics
Statistical analysis was performed for experiment 2.5 - Growth analysis of Herc5
transfected cells. Data was analyzed using a two-way ANOVA in the GraphPad Prism 5
program, p values less than 0.05 were considered significant.
Chapter 3: Results
3.1 Generation of Herc5 mutants and RNA expression
Since the E3 ligase function (HECT domain) of Herc5 was shown to be unnecessary for
Herc5 to restrict HIV-1 release, the characterization of both the spacer and RLD was
necessary to understand the mechanism by which Herc5 was acting as a viral restriction
factor. To understand the physiological relevance of the Herc5 spacer and RLD domains,
the generation of domain deletions of both the RLD and Spacer regions was essential.
Experiments performed with these mutant constructs of Herc5 would allow us to observe
the relevance of each domain to Herc5’s function. To determine the importance of the
RLD for Herc5 restriction of virus, truncations of the RLD were generated using PCR
amplification. Forward primers recognizing each blade of the RLD created increasingly
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larger truncations of the domain when paired with a reverse primer recognizing the end of
the coding region of Herc5 (Fig. x, Supplementary Table 1). A total of 7 deletions were
made in this domain and were amplified using PCR (Supplementary Table 2). These
deletions were subcloned into the pFLAG vector. Only Al, A1-3, and A1-7 RLD (ARLD)
were successfully cloned into pFLAG based on sequencing analysis. Western blot of
U 20S cells transfected with the pFLAG RLD mutants was performed to test protein
expression of the mutant constructs. Wild type CS2+Herc5 was used a positive control
and gave a product of 117kDa. A protein product of roughly 105kDa, 95kDa, and 80kDa
was to be expected for successful detection/expression of 1, A1-3, and A1-7 RLD (ARLD)
respectively. However, none of these mutant constructs were detectable (Fig. 1). MG 132
(Sigma) and amantadine-hydrochloride (Sigma) were used to inhibit the proteasome and
lysosome respectively to determine if the protein products were being degraded by either
of these enzymes. However, no enhancement in expression of the RLD constructs was
observed. The A1-2, A1-4, A1-5, A1-6 RLD pFLAG clones were also unable to be
obtained. Since A l, Al -3, and ARLD pFLAG mutants were unable to express protein
and A1-2, A1-4, A1-5, A1-6 RLD mutants were not easily cloned into the pFLAG
backbone, RLD mutants were re-cloned in a CS2+ plasmid backbone. Primers were
redesigned to generate the RLD mutants using modified site directed mutagenesis from
the CS2+ WT Herc5 construct. Using modified site directed mutagenesis Al-2, Al-5, and
A1-7RLD (ARLD) were successfully generated in the CS2+ plasmid backbone. Modified
site directed mutagenesis was also used to generate the Aspacer mutation. All constructs
were sequenced at Robarts Sequencing Facility and verified using GENtle bioinformatics
software. U20S cells, which do not express Herc5 and therefore eliminated any potential
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Fig. 1 Western blot for protein expression of pFLAG Herc5 RLD mutants in
comparison to pCS2+ WT Herc5. Polyclonal Herc5 antibody (Abnova) was used to
blot for Herc5 constructs. IOuM MG132 (Sigma) was used to inhibit the proteasome and
0.5mM amantadine-HCl (Sigma) was used to inhibit the lysosome. DMSO was used as a
control for both MG132 and amantadine effects. Ubiquitin was used as a negative
control. Transfections were done using FuGene transfection reagent and harvested 24
hours later. Data shown is representative of two independent trials (n=2).
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Fig. 2 RTPCR of CS2+ Herc5 constructs from U 20S transfected cells. U20S cells
were transfected with the Herc5 constructs as they are a natural knockdown of Herc5.
Total mRNA was extracted 24 hours later and reverse transcribed into cDNA which was
then PCR amplified using a forward primer beginning at the spacer region and reverse
primer beginning at the end of the HECT domain. For the Aspacer mutant of Herc5,
primers were used so that only the HECT domain was amplified. Al construct displayed
in this 1%DNA agarose gel is in the pFLAG backbone and is part of the first set of Herc5
mutants cloned into the pFLAG backbone. The Herc5 constructs which display mRNA
production were those cloned in the CS2+ plasmid backbone.
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for background Herc5 mRNA detection, were transfected with mutant constructs and RT
PCR was performed to test expression of mRNA (Fig. 2). mRNA production was
detectable for all CS2+ Herc5 mutant constructs.
3.2 Effect of Herc5 on cell viability and growth
Observations made in preliminary studies suggested that Herc5-transfected cells
grew more slowly than non-Herc5 transfected cells (DMEM colour changed due to
greater acidity in media from high confluency of pGL3 transfected and non-transfected
cells). In addition, defects in nucleocytoplasmic shuttling of mRNA show retarded
growth via restriction of cell cycle in the G2/M stage [131,133,134]. If Herc5 was
affecting nucleocytoplasmic shuttling of HIV-1 mRNA, retarded growth would be
expected in Herc5 transfected cells. To determine whether Herc5 was affecting
replication of cells through this mechanism, growth curves were generated for WT Herc5
and mutant construct transfected HeLa cells over a period of 4 days. Interestingly, Herc5
transfected cells showed a much slower rate of replication in comparison to cells
transfected with a promoterless plasmid (pGL3) (Fig. 3). Eliminating E3 ligase activity
(C994A) and spacer region of Herc5 did not affect the ability of Herc5 to slow the cell
cycle. However, cells transfected with the ARLD Herc5 constmct displayed a growth
pattern comparable to that of the negative control. In addition, when any of the blades of
the Herc5 RLD were deleted (A1-2RLD and A1-5RLD) the rate of growth was also
comparable to ARLD transfected and pGL3 transfected cells (Fig. 3, Supplementary
Table 3). This suggests that the RLD of Herc5 is important for the regulation of cell
cycle progression and that even a small deletion of its structure will eliminate Herc5’s
ability to restrict cell cycle. Additionally, this supports the hypothesis that the RLD may
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be affecting nucleocytoplasmic shuttling of mRNA by displaying a comparable
phenotype. Cell viability tests were also performed on the Herc5 construct transfected
cells in which both live and dead cells were counted for each construct. There was no
significant difference in the viability of cells when compared across the mutant constructs
(data not shown).
3.3 Propidium Iodide staining for cell cycle analysis
Defects in nucleocytoplasmic shuttling of mRNA results in retarded cell cycle,
predominantly in the G2/M stage of cell cycle [131]. Section 3.2 demonstrated retarded
cell cycle in Herc5 transfected cells; however the stage cell cycle restriction is not clear
(if at all). To determine whether Herc5 generates an arrest of cell cycle and whether it is
similar to the arrest seen in nucleocytoplasmic mRNA shuttling defective cells (at the
G2/M stage of cell cycle), propidium iodide staining for DNA content of cells transfected
with WT Herc5, C994A, spacer or RLD mutant constructs was performed and analyzed
using flow cytometry. During interphase of the cell cycle, nuclear DNA content of cells
duplicates to prepare for mitosis. By the end of G2, the end of interphase, cells contain
twice as much DNA as in G l, the beginning of interphase. S phase which occurs
between the two stages is the onset of DNA duplication and therefore contains more
DNA than Gl but not as much DNA found in G2. The intensity of the PI stain correlates
with the amount of DNA in cells and therefore is used to determine the stage of cell cycle.
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Fig . 3 Growth comparison of Herc5 constructs in HeLa cells. Transfection of HeLa cells
was performed using SuperFect transfection reagent. Experiment was performed in triplicate.
The mean of three trials was plotted for each day for each construct. Growth rates of all
construct transfected cells were compared to pGL3 negative control. Significant differences
in growth were observed for WT, C994A, and ASpacer (p < 0.05) (n=3)
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Hydroxyurea, a drug which arrests cell cycle at G l, was used as a positive control for the
detection of changes in cell cycle (Fig. 4, panel B). Cells were transfected using FuGene
and harvested 48 hours later. Interestingly, 11.25% more Herc5 transfected HeLa cells
were in G2 or M phase of the cell cycle than cells transfected with pGL3 (Fig. 4 panel, C
and D). This growth characteristic was also observed in cells transfected with the C994A
mutant meaning the E3 ligase activity of Herc5 is not required for the restricted growth
seen in HeLa cells (Fig. 4, panel E). However, the ARLD mutant did not demonstrate a
large proportion of cells in G2 and resembled cells which had been transfected with the
pGL3 (Fig. 4 panel F). This further suggests that the RLD of Herc5 is necessary for the
arrested growth seen in Herc5 transfected cells at the G2 phase or M phase of cell cycle.
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Fig. 4 Propidium Iodide staining for cell cycle analysis of HeLa cells transfected with Herc5
constructs. Cells were transfected with FuGene transfection reagent and harvested 48 hours
later. Cells were fixed for 2 hours in 70% ethanol before being stained with PI. A) untransfected
cells were used as a negative control B) ImM Hydroxyurea was used to arrest cell cycle. C-F)
Transfected cells. ModFit LT™ was used to analyse cell cycle. Manual analysis was needed for
C994A and hydroxyurea data as peaks were not clearly discemable by the predictive software.
The gates for these panels were modeled off gates used for Herc5. Experiment was carried out
only once (n=l).
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3.4 N u cle a r m o rp h o lo gy

Unusual nuclear morphologies have been described for cells which are defective
in nucleocytoplasmic shuttling of mRNA due to deficiencies in nuclear membrane
assembly [135]. Since cell cycle analysis experiments of Herc5 transfected cells have
shown similar growth characteristics to cells defective in nucleocytoplasmic shuttling of
mRNA, the exploration of the nuclear morphology was logical. To observe the
phenotype of Herc5 transfected cells and see if they displayed abnormal nuclear
morphologies, immunofluorescence labelling of HeLa cells transfected with the various
Herc5 constructs was performed and visualized using confocal microscopy. DAPI
staining was used for nuclear staining. Interestingly, Herc5 transfected cells had 48%
more C-shaped nuclei or nuclei which were lobed and appeared to be dividing into new
cells than pGL3 transfected. This same morphology was seen for cells transfected with
the C994A mutant of Herc5 (41.5% more than pGL3) as well as the Aspacer mutant (48%
more than pGL3). This phenotype was eliminated when the ARLD Herc5 mutant was
transfected. When any of the blades of the RLD were deleted (Al-2 or A1-5) the cells
still displayed the phenotype representing pGL3 transfected cells which suggests that the
full intact RLD structure is necessary for any morphological changes (Fig. 5).
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Fig. 5 Lobed nuclear morphology of Herc5 transfected cells. A) confocal microscopy
performed on Herc5 construct transfected cells (lipofectamine transfection) Red=Flag
tagged Herc5, DAPI/Blue= nucleus. White arrows highlight lobed nuclear morphology,
red arrows indicate normal nuclear morphologies. B) percent of cells displaying lobed
nuclear phenotypes. At least 100 cells were counted from each Herc5 construct. No
statistical analysis could be performed on this data as the experiment was only carried out
successfully one time (n=l).
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3.5 R e v L o c a liz a tio n

Preliminary results showing a restriction of HIV-1 protein production but
increased levels of mRNA suggested Herc5 may be impacting the ability of HIV-1
mRNA to shuttle into the cytoplasm. Since the HIV-1 Rev protein is an accessory
protein required for shuttling of HIV-1 mRNA into the cytoplasm it was logical to test
whether Herc5 was impacting nucleocytoplasmic shuttling of HIV-1 mRNA by altering
Rev activity. In the absence of vRNA, Rev is able to shuttle host mRNA into the
cytoplasm, therefore this experiment was done without the use of replication competent
HIV-1 and only with Rev to specifically examine the effects of Herc5 on its localization.
If Herc5 has any effect on Rev’s ability to shuttle mRNA from the nucleus, it would still
be detectable in the absence of other HIV-1 RNA. Alterations in Rev’s ability to shuttle
HIV-1 mRNA into the cytoplasm would be accompanied by an observable change in
localization of the rev protein - particularly an inability of Rev to shuttle to the cytoplasm
and export cellular mRNA in the presence of Herc5. To assess the effect of Herc5 on
Rev localization, HeLa cells were co-transfected with one of the various Herc5 constructs
and the HIV RNA shuttling protein Rev at an 8:1 ratio. Cells were stained using an antiRev antibody and immunofluorescent anti- mouse secondary antibody. DAPI was used
to stain the nucleus. Cells transfected with any of the Herc5 constructs or with
promoterless vector (pGL3) did not display altered Rev localization. All Rev transfected
cells showed Rev contained in the nucleolus of the nucleus where a large concentration of
ribosomal RNA is known to be located and transcribed. Rev was not readily detectable
in any other cellular compartment or in the cytoplasm (Fig. 6).
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Fig. 6 Rev Localization in HeLa cells transfected with Herc5 mutant constructs. Rev was
co-transfected with one of the Herc5 constructs. With each treatment, Rev was found only to
localize in the nucleolus of cells. No other localization of Rev or other phenotypes were seen.
Red= rev, DAPI/Blue= nucleus. Transfections were performed using lipofectamine (n=3)
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Chapter 4: Discussion
4.1 Summary and Interpretation of Data
In summary, our lab has identified a novel HIV restriction factor, Herc5 which
may be able to restrict HIV release via two mechanisms: 1) the inhibition of virus release
by its E3 ligase and ISGylation of gag, and 2) the inhibition of protein synthesis likely
due to an inhibition of RNA trafficking to the cytoplasm for translation resulting in
decelerated growth. We have shown that this second mechanism of HIV restriction is not
due to Herc5’s E3 ligase function since mutating the key C994 residue to alanine, which
is necessary for Herc5’s ligase activity, did not interfere with Herc5’s ability to restrict
vims translation. Therefore, creation of Herc5 domain mutants was necessary for
comprehending the mechanism by which Herc5 is able to restrict HIV at a pretranslational step. An HIV release assay performed by Matthew Woods (Woods, M„ et
al., 2011; unpublished) using the RLD and spacer mutants demonstrated the RLD of
Herc5 to be important for this second mechanism of restriction due to the inability of
ARLD Herc5 to restrict vims production. Additionally, the same experiment
demonstrated that the spacer domain of Herc5 was not necessary for Herc5 in restricting
HIV-1 release. Based on this result as well as preliminary studies that showed increased
levels of mRNA (that is not being translated into protein) in the presence of Herc5, we
hypothesized that the RLD of Herc5 may be preventing the shuttling of mRNA in the
cytoplasm. To test our hypothesis, growth curves of HeLa cells transfected with various
domain mutants of Herc5 (including ARLD, Al-2 RLD, A1-5RLD) were performed.
Growth curve experiments showed that while WT Herc5 showed restricted or retarded
cell cycling, the ARLD Herc5 and bladed deletions (Al-2, A1-5 RLD) constructs were
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able to grow at a rate comparable to cells transfected with a promoterless (pGL3) vector.
Propidium iodide staining for nuclear content to determine cell cycle stage demonstrated
Herc5 constructs were predominately found in G2 or M phase, whereas the ARLD and
bladed mutants did not demonstrate any altered cell growth pattern and were
predominately found in G1 phase like in pGL3 transfected cells.

Based on these results,

we have shown that Herc5 is a mediator of cell cycle progression through the activity of
its RLD. Additionally, the effects of Herc5 on nuclear morphology are eliminated with
any of the RLD mutants which show an increasing reliance of Herc5 on the RLD for its
activity.
To elucidate the mechanism and significance of the RLD it must be compared to
its most similar homologue, RCC1. Structurally, the RLD is almost identical to the RCC1
protein (Fig. v). As mentioned earlier, the RCC1 is a key regulator of mRNA export to
the cytoplasm by acting as a GEF for the Ran GTPase, exchanging Ran-GDP for RanGTP. This causes a build up of Ran-GTP in the cytoplasm which generates a GTP
energy gradient across the nuclear membrane by which mRNA shuttles across.
Interestingly, experiments looking at Herc5 interacting proteins have identified Ran as a
binding partner [132- supplementary data].

Due to the high degree of structural

homology between the RCC1 and RLD of Herc5 and that Ran is thought to interact with
Herc5 and RCC1, it may be possible that the RLD is interacting with Ran similarly to its
homologue RCC1 and functioning as a GEF for Ran-GDP converting it into Ran-GTP.
Although this has not been directly tested, it has been suggested that Herc5 may act as a
GEF for small GTPases like Ran [215]. If this were to occur in the cytoplasm (where
Herc5 is found), Herc5 GEF activity may be able to counteract the GTP energy gradient
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that normally exists across the nuclear membrane that is required for mRNA shuttling and
inhibit or reduce the export of mRNA into the cytoplasm. In addition, cells which are
unable to hydrolyze Ran-GTP in the cytoplasm and therefore do not have a defined GTP
energy gradient across the nuclear membrane show an arrest at the G2/M stage of cell
cycle similar to what we have seen in the presence of Herc5 [133,134], If the RLD of
Herc5 is acting as a GEF for Ran-GDP, it is possible that its conversion into Ran-GTP in
the cytoplasm outweighs the rate of hydrolyzing Ran-GTP leading to defective mRNA
shuttling and cell cycle possibly an arrest at G2/ M phase. In the presence of ARLD
Herc5 mutant, the G2/M cell cycle profile seen in WT Herc5 is abolished and resembles
the pGL3 negative control. If the RLD of Herc5 is maintaining GEF activity for Ran, we
would expect that the deletion of this domain would also display the same phenotype as
we have observed in our ARLD cell cycle experiments, where ARLD Herc5 does not
affect cell cycle. That is, deletion of the potential GEF acting domain, ARLD, would
eliminate cytoplasmic Ran-GDP conversion to Ran-GTP by Herc5. Thus there would no
longer be an equalization of Ran-GTP across the nuclear membrane caused by Herc5
GEF activity and instead the cell would resume a normal build up of nuclear Ran-GTP
which therefore would allow shuttling of mRNA to the cytoplasm. To further implicate
the RLD in Herc5 cell cycle, the E3 ligase activity of Herc5 of Herc5 was necessary for
the G2/M phenotype since deletion of these features did not affect the cells’ G2/M profile
in PI staining experiments.
It was unfortunate that there were technical issues in the processing of the Aspacer
and bladed mutants of the RLD for PI staining and cell cycle analysis. This data would
have been valuable in determining whether or not the spacer domain showed the same
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G2/M phenotype and allow for greater confidence that the RLD is responsible for the
G2/M phenotype. The bladed mutants would have also helped to determine whether the
full RLD structure is necessary to observe the cell cycle mediating effects of Herc5.
Based on the cell viability and growth analysis experiment, my assumption would be that
since the spacer domain maintained slowed growth and that cells transfected with the
bladed mutants had normal growth rates, the spacer domain would not be necessary to
observe the G2/M phenotype whereas either of the bladed mutations would have shown
regular cell cycle progression. Processing issues such as these and fewer than 10,000
cells analysed for certain samples during the PI staining experiment make it increasingly
important for the experiment to be repeated at least twice more. The use of 10cm dishes
would be more appropriate so that at least 20,000 cells could be collected from each
sample and therefore claims of cell cycle arrest would be more statistically relevant. In
addition, hydroxyurea treated cells were inhibited almost entirely in G1 and S phase
therefore eliminating a second G2 peak. As a result, the ModFit software was not
accurately able to model cell cycle peaks automatically for hydroxyurea treated cells. As
well, C994A transfected cells displayed a large amount of background staining which
also affected ModFit automatic prediction of peaks. Instead, these samples were assessed
manually using the same gates used for the analysis of Herc5 cell cycle. Repetition
would allow for statistical analysis to be carried out and greater confidence that the
results observed are not artificial and reproducible.
RT PCR of Herc5 constructs was performed instead of protein detection using
western blot due to an inconsistency for detection of Herc5 protein. Inconsistency in
protein detection was not due to transfection since mRNA of Herc5 constructs was
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successfully reverse transcribed from U 20S (natural Herc5 knockdowns with no basal
production of Herc5). However, Herc5 construct proteins were detectable using confocal
microscopy of transfected HeLa cells using the same antibody used for western blot (antiFLAG). Although HeLa cells are not natural Herc5 knockdowns, the use of FLAG
antibody instead of Herc5 antibody allows for detection of only transfected Herc5
constructs. HeLa cells are also much more susceptible to taking up plasmid and therefore
are higher expressers of transfected protein. It is possible that the ability to detect Herc5
in confocal microscopy is due to the use of a different cell type rather than a change of
detection method. It is also possible, however, that the change in detection ability is due
to a change in secondary antibody that was used for confocal microscopy and not for
western blot. It might be of greater value to perform nickel column pulldown of Herc5
mutant construct transfected cell lysates. However, re-generation of the Herc5 mutants
would need to be done so that they would express a HIS tag needed for the nickel column
assay. Performing this assay would allow for greater ability to assess stability of the
protein and should be done in parallel with drugs inhibiting proteasomal (MG 132) and
lysosomal (amantadine) degradation to ensure they are not being prematurely degraded.
Although it is clear that Herc5 transfected cells have altered cell cycle, growth,
and are predominately in G2/M stage of cell cycle, it cannot be determined whether the
altered growth of Herc5 transfected cells is due to an irreversible arrest of cell cycle at
G2/M or a prolongation of G2/M phase based on the experiments performed. Studies that
have previously investigated the effects of defective mRNA shuttling to the cytoplasm
suggest that cell cycle is restricted rather than prolonged [131,133]. Deursen et al,
showed that defects in the CAN protein, which is necessary for nuclear pore formation
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and shuttling of mRNA out of the nucleus, causes an arrest of cell cycle predominately in
G2 stage. Additionally, Ren et al showed a restriction of cell cycle at G2 when there was
accumulation of mRNA in the nucleus and impaired GTP hydrolysis in the cytoplasm. If
Herc5 is affecting shuttling of mRNA into the cytoplasm, it is possible that the G2 cell
cycle phenotype is due to cell cycle arresting rather than prolongation. However, it has
also been noted that increases in the cytoplasmic Ran-GTP binding protein RanBPl,
which acts as a co-factor for the Ran-GTP hydrolyzing protein RanGAPl, lead to
prolonged mitosis in mammalian cells [136]. Increases in Ran-GTP in the cytoplasm due
to Herc5 may cause an upregulation of RanBPl and affect cell cycle in this manner which
might suggest Herc5 is resulting in slower growth of cells rather than restriction in cell
cycle. In experiment 3.2, growth analysis was performed on Herc5 and mutant construct
transfected cells. Although WT Herc5, C994A, and Aspacer transfected cells all
displayed slower rates of growth, these cells all continued to grow until they reached 100%
confluency. This would suggest that growth of these cells was only slowed rather than
restricted, however, since transfection rate is not 100% it cannot be ruled out that cells
transfected with Herc5 were restricted in growth while untransfected cells in the well
continued to grow until the well reached confluency. An important observation that was
observed in the Deursen et al study was a normal nuclear envelope assembly of G2
arrested cells. Since we observed abnormal nuclear morphologies in the presence of
Herc5 it is possible that cell cycle restriction at G2/M is less likely.
The nuclear morphology experiment shows that the abnormal cell cycling of
Herc5 transfected cells is accompanied with a c-shaped or multi-lobed nuclear phenotype.
This phenotype can also be supported by a defunct Ran-GTP gradient across the nuclear
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membrane. It has been shown in Xenopus egg extracts that increased cytoplasmic RanGTP disrupts proper assembly of the nuclear envelope leading to abnormally small
nuclear morphologies albeit not the same morphologies as we have seen in HeLa cells
[224]; however this may be due to cell line variability. Particularly, Ran-GDP in the
cytoplasm is necessary for proper nuclear envelope fusion in the process of nuclear
assembly [136]. If the Herc5 RLD is contributing to an increased cytoplasmic Ran-GTP
concentration by acting as a GEF for Ran, it may lead to the abnormal nuclear
morphologies we have observed in HeLa cells transfected with WT Herc5. Herc5
lacking E3 ligase function (C994A) and ASpacer Herc5 also display abnormal nuclear
morphologies as shown in Figure 5 further implicating the importance of the RLD in this
Herc5 phenotype and suggesting that mRNA shuttling defect, cell cycle irregularity, and
nuclear morphology abnormality are all due to RLD activity. Interestingly, the use of any
of the bladed RLD mutants showed morphology phenotypes that were comparable to
pGL3 transfected cells, which strongly suggests the importance of the entire domain in
Herc5’s cell cycle activity and impact on nuclear morphology. However, this experiment
must be repeated at least two more times since it was only performed once successfully
and thus no statistical significance can be claimed.
In an HIV-1 release assay using pGL3, WT Herc5, C994A, ASpacer, and ARLD
mutants, the ASpacer and C994A Herc5 constructs show equal if not more potent effects
in comparison to the WT Herc5 (data not shown) (Woods, M., et al 2011; unpublished).
Additionally, although nuclear morphology experiments show a similar propensity for
lobed nuclei to occur in WT transfected cells as C994A or ASpacer constructs, both
C994A and ASpacer mutants show a more pronounced abnormal lobed phenotype. These
-
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observations may be explained by the hypothesis that Herc5 might autoregulate itself
through ISGylation of its spacer domain to subsequently shutdown the protein function.
Therefore, eliminating the E3 ligase activity of Herc5 by C994A point mutation or
deletion of the spacer domain could be increasing Herc5 stability, prolonging its activity
and subsequently enhancing its effects by preventing/slowing turnover. Western blots
performed on Herc5 construct stability show that of all Herc5 modified site directed
mutagenesis generated constructs, the Aspacer mutant is most stable (data not shown). It
would be important to do a stability trial for the C994A mutant as well to see if the
protein is as stable as the Aspacer construct. The other well known ISG15 conjugating
E3 ligase, EFP, also contains a domain in which multiple alpha helices reside similar to
the spacer region of Herc5. AutoISGylation of this domain by EFP leads to negative
regulation of its expression and protein turnover [139]. Future experiments should
include immunoprécipitation of all Herc5 constructs from transfected cell lysates to
compare the levels of intracellular protein. Although immunoprécipitation is only semiquantitative, large differences in protein expression would be considered significant. If
this hypothesis is correct it may help to explain some unusual results seen in the PI
staining experiment. Particularly, large amounts of background staining seen for C994A
transfected cells which affected ModFit ability to automatically predict peaks for G l, S,
and G2. It is possible that the wide peaks for the C994A mutant were due to an
incomplete digestion of RNA in cells. Although all cells were treated with RNaseA for
an equal amount of time (20 minutes), cells transfected with Herc5 and C994A may have
increased levels of RNA in the nucleus if our hypothesis that the RLD domain is
restricting trafficking of RNA into the cytoplasm is correct. In addition, C994A may
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have even greater amount of RNA build up than Herc5 if the construct is in fact more
stable than wild type Herc5. It would be interesting if this wide peak phenomenon was
also seen in cells transfected with ASpacer Herc5, again since this construct may be more
stable and therefore have exaggerated and prolonged effects on cell cycle.
Immunofluorescence of Rev in HeLa cells co-transfected with Herc5 constructs
demonstrated that no differences in Rev localization could be detected between any
samples. Perhaps due to high the concentration of mRNA that is located in the nucleolus,
Rev predominately localizes here and only few Rev molecules are necessary to shuttle
RNA to cytoplasm. If such is the case, immunofluorescence may not be sensitive enough
to detect cytoplasmic Rev or changes in levels of Rev in the cytoplasm. It should be
expected that in pGL3 transfected cells, Rev would be detectable in both the nucleus and
cytoplasm. However, if in the negative control Rev is undetectable in the cytoplasm by
confocal microscopy, defects in Rev ability to shuttle mRNA into the cytoplasm in the
presence of Herc5, as we would expect, would also be undetectable. It is important to
find another assay to establish whether or not Herc5 is affecting Rev shuttling in order to
determine the mechanism by which Herc5 affects HIV-1 protein production. If Herc5 is
able to act as a GEF for Ran in the cytoplasm and offset the GTP gradient across the
nuclear membrane, then it would be expected that Rev, which uses the same GTP energy
gradient to shuttle HIV-1 mRNA into the cytoplasm, would also be affected and perhaps
unable to shuttle out of the nucleus. (See Future directions 4.21 for proposed Rev
localization assay).
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4.2 Future directions
4.21 Quantification o f cytoplasmic Rev in the presence ofHerc5 vs pGL3 and
ARLD transfected cells
Future directions should include an assay that assesses the amount of cytoplasmic
rev in the presence of Herc5 vs. ARLD Herc5 and pGL3. This would allow us to
examine the affect of the RLD of Herc5 on Rev shuttling into and out of the nucleus and
further suggest that Herc5 may be affecting the GTP gradient that is required for Rev to
shuttle mRNA out of the nucleus.

For quantitative analysis of cytoplasmic and nuclear

Rev, separation of the two cellular compartments would have to be performed in order to
determine their Rev concentrations individually. The ProteoJET™ cytoplasmic and
nuclear protein extraction kit could be used for the separation of the cytoplasmic and
nuclear fractions of cells transfected with the different Herc5 constructs. Lysates from
both the cytoplasmic fraction and nuclear fractions could be run separately on an SDS
page gel and blotted for rev contents. Cytoplasmic fractions can be quantitatively
compared across samples to determine if there is a difference in rev levels when co
transfected with Herc5 vs. pGL3 (promoterless vector - negative control).
4.22 gRTPCR o f HIV mRNA in cytoplasm and nuclear fractions to evaluate
shuttling ability in the presence ofHerc5 and mutant constructs
qRTPCR could be done for HIV protein mRNA in the cytoplasm and nucleus to
determine any differences in mRNA shuttling/distribution that may exist between Herc5
ARLD and wild type Herc5 transfected cells. This data would complement the Rev
localization data mentioned above. Increased levels of HIV mRNA that are found with
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wild type Herc5 may be abolished in the presence of ARLD Herc5, which would suggest
that this domain is required to restrict the shuttling of HIV mRNA. For example,
ultracentrifugation (as an alternative to the ProteoJET™ cytoplasmic and nuclear protein
extraction kit) of these cells would be performed to separate nuclear and cytoplasmic
fractions. mRNA could be isolated from these fractions and digested to remove DNA.
mRNA would then be reverse transcribed into cDNA and could be amplified by PCR
with specific primers for HIV protein sequences such as gag forward and reverse primers.
This would allow us to quantitatively measure the differences between cytoplasmic and
nuclear mRNA in the presence of the Herc5 mutant constructs vs. the wild type and
negative control. Again, if the ARLD mutant of Herc5 shows similar distribution of
mRNA in the cytoplasm and nucleus as the negative control, it would further implicate
the RLD in regulating cytoplasmic export of mRNA perhaps through GEF activity.
4.23 Quantification o f cytoplasmic Ran-GTP in the presence o f Here 5 vs. pGL3
nesative control and mutant constructs
To determine if Herc5 has an effect on cytoplasmic Ran-GTP levels, a Ran
activation assay kit can be used (Cell Biolabs). This kit uses RanBPl (a Ran-GTP
hydrolyzing enzyme that specifically recognizes GTP bound Ran) agarose beads to
selectively pull down activated Ran from cell lysates. Herc5 and mutant construct
transfected cells would be harvested and separated of cytoplasmic and nuclear contents
through the previously described methodologies. The Ran activation assay kit could be
used on the cytoplasmic fraction to quantitatively determine the concentration of RanGTP found in the cytoplasm. Cytoplasmic Ran-GTP would be compared in cells
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transfected with pGL3, WT and mutant (specifically ARLD Herc5) by immunoblotting
for Ran.
4.24 Generation ofRLD active site mutants to evaluate the impact on Herc5 GEF
activity (if any), mRNA shuttling capacity, nuclear morphology, cell cycle
progression, growth curve, and rev localization.
Currently we have designed three mutants of Herc5 which contain point mutations within
the RLD. We wanted to test the importance of these residues since the homologous sites
in RCC1 serve as active sites for RCC1 GEF activity towards Ran [220]. Reduced
competency in Herc5 to restrict HIV or mRNA shuttling into the cytoplasm with one or
all of these mutations would allow us to further characterize the importance of this
domain for HIV restriction. These RLD point mutants should be compared to the ARLD
mutant and the wild type Herc5 construct in the aforementioned experiments to determine
if they completely abolish GEF activity (if any), mRNA shuttling of Herc5, and restrict
cell cycle. If so, not only would we have strongly implicated the RLD as a GEF for Ran
but also determined key active site residues of Herc5 that are necessary for HIV-1
restriction.
4.25 Generation o f an RLD only construct lacking spacer and HECT domains o f
Herc5
Primers have already been made to amplify the RLD region of Herc5 in the
absence of the other domains. It would be interesting to see if this region alone would be
able to counteract the Ran-GTP gradient across the nucleus by still acting as a GEF for
Ran (if possible) and thus restrict HIV protein production. This would allow us to further
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understand the significance of this domain and possibly suggest evolutionary origins of
Herc5. Should the domain be able to maintain its GEF activity (if any) and be able to
restrict mRNA shuttling, it might suggest that the domain was once a singular protein and
either further evolved to contain a spacer and RLD domain perhaps by associating with
an ancient ISG15 E3 ligase to acquire stronger antiviral activity.
4.26 Generation o f point mutants at lysine residues in the spacer domain to
determine ifautoISGvlation in this domain leads to Herc5 turnover.
To determine the significance of the increased stability seen with the Aspacer
Herc5 construct, point mutations of the lysine residues (where ISGylation occurs [218])
of the spacer domain should be made. Since the other ISG15 E3 ligase, EFP, contains a
coiled coil domain that is structurally similar to the spacer domain of Herc5 and is
autoISGylated to influence protein degradation, it would be interesting to see if the spacer
domain of Herc5 has the same activity. Firstly, stability trials of wild type Herc5
transfected cells in the presence of a deubiquitinating enzyme such as Ubp2 should be
performed to determine if protein turnover is due to ubiquitination. Provided that
deubiquitination of Herc5 does not increase protein stability, stability trials of wild type
Herc5 should be performed in the presence of the de-ISGylating enzyme, Ubp43 and
compared to the C994A Herc5 mutant (lacking ISG15 conjugative activity) and wild type
Herc5 alone. An increase in stability of the Herc5 construct in the presence of Ubp43
compared to wild type Herc5 and similar to C994A Herc5 stability would suggest that
autoISGylation of Herc5 is causing turnover. Next, the spacer domain lysine residue
point mutants should be transfected into cells and analyzed for stability and compared to
wild type Herc5 stability. This would allow us to determine which residues are necessary
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for Herc5 turnover most likely due to ISGylation. To further assess if this is a site for
ISG15 binding, wild type Herc5, Aspacer Herc5, and the lysine residue mutated spacer
domain of Herc5 should be transfected into cells in the presence of ISG15 and then
immunoprecipitated in the presence of Herc5 (or flag) antibody. The bound product can
then be run on a non-denaturing SDS page gel and blotted for ISG15 to determine the
capacity of each construct to be modified with ISG15. An inability of ISG15 to bind to
Aspacer and ability to bind to wild type Herc5 would definitively prove the region is
ISGylated. With the individual lysine residue point mutants in the spacer domain of
Herc5, we can also determine the exact lysines which are targets for autoISGylation.
Completion of these experiments would elucidate some of the functional properties of the
spacer domain of Herc5.
4.27 Evolutionary comparison ofHerc5 across various primate species.
In the future, it would also be very interesting to determine the evolutionary conservation
of Herc5 amongst primates. Since Herc5 is found in only primates, Herc5 from different
primate cell lines can be reverse transcribed using human Herc5 primers- initially.
Although these human primers may not be able to amplify Herc5 proteins that exist in
other primate species due to sequence variability, some primate species that are
sequentially identical or highly similar may yield a Herc5 protein sequence. If not, Herc5
sequences of Rhesus macaques, northern white faced gibbons, Sumatran orangutans,
marmosets, and chimpanzees from any of which Herc5 primers can be made. These
primers would begin in the non-coding regions of Herc5 so that the coding region of the
primate Herc5 sequence would be intact and not contain nucleotide differences that may
be present if using human coding region Herc5 primers. These evolutionary comparisons
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of proteins across species have been performed for other HIV restriction factors such as
TRIM22 and TRIM5a. These studies show that the prevalence of TRIM22 and TRIM5a
within mammalian species is highly selective favouring one protein or the other.
Specifically, the selection of TRIM22 over TRIM5a in new world monkeys and humans
has occurred over the last 23 million years possibly reflecting a change in pathogenic
environment [217]. Herc5 isolated from various primate cell lines could be tested on
their ability to restrict HIV (or SIV) to assess their antiviral activity and possibly allow us
to observe when in evolutionary history Herc5 acquired antiviral activity-particularly by
comparing Herc5 antiviral activity in old world and new world monkey cell lines.
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Supplementary Figures

Supplementary Figure 1. HECT E3 ligase ubiquitin conjugation vs. RING E3 ligase
ubiquitin conjugation [223].
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Supplementary Figure 2. pCS2+ plasmid map. Original WT Herc5 construct was
cloned in this backbone.
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Supplementary Table 1- Primers used for generation of pFLAG Herc5 RLD mutants.

Mutant
A1 RLD

Forward primer 5’ -> 3’
ACG TAG ATC TAG TAG
GGT GGA GGT GAC GC

Al-2 RLD

ACG TAG ATC TAG TCA
AGG AGC AGA GCA CAT
GC
ACG TAG ATC TAT GGG
TGG TGA GCT TTT TGC
CTGG
ACG TAG ATC TAT GTC
CAT GTC TGG CAA CAT
TTA TTC ATG G
ACG TAG ATC TAT GGA
TGG GCT GCT GTT TAC
TTTCGG
ACG TAG ATC TAT GGG
AAA GGT CTT TTC CTT
TGG TTC TGG
ACG TAG ATC TAT GAT
GAT TGC TGG AGG GAA
TCA AAG C
ACG TTC TAG ATC AGC
CAA ATC CTC TG

Al-3 RLD

Al-4 RLD

A1-5 RLD

A1-6 RLD

A1-7 RLD (all RLD)

Herc5 coding region reverse
primer
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Supplementary Table 2. PCR conditions for amplification of pFLAG Herc5 RLD
constructs

A.
5ul
6ul
lui
lui
lui
2.5ul
120ng
lui
To 50ul
50ul

lOx pfu reaction buffer w/o MgS0 4
M gS04
dNTP
Forward primer
Reverse primer
DMSO (5%)
Template CS2+Herc5
pfu
water
Total volume

B.
Temperature

Time

# of cycles

Initial Denature

95 °C

3 minutes

lx

Denature

95°C

30 seconds

32x

Annealing

50.5°C

30 seconds

32x

Extension

72°C

4 minutes

32x

Final Extension

72°C

10 minutes

lx
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Supplementary Table 3. Statistical analysis of cell cycle growth curve generated using twoway ANOVA in GraphPad Prism 5.

Two-way RM ANOVA
Source of Variation
Interaction
Day
Treatment
Subjects (matching)
Source of Variation
Interaction
Day
Treatment

Matching by cols
% of total variation

P value

4.71

0.0004

82.83
7.97

< 0.0001
< 0.0001

0.8137

0.5766

P value summary

Significant?

***

Yes

■kirk*
****

Subjects (matching)

ns

Source of Variation
Interaction

24

Yes
Yes
No

DfSum-of-squares Mean square
1.475e+011

F

6.145e+009

2.994

Day

4

Treatment

6

2.594e+012 6.486e+011
2.497e+011 4.162e+010

22.86

Subjects (matching)

14

2.548e+010 1.820e+009

0.8869

Residual

56

1.149e+011

2.052e+009

Difference

0

Number of missing values
Bonferroni multiple
comparisons
pGL3 vs WT
Treatment

316.0

Number of
comparisons: 30

pGL3

WT

Day 1

36000

43000

7000 -112607 to 126607

Day 2
Day 3

127000
283333

59000
146667

-68000 -187607 to 51607
-136667 -256273 t o -17060

Day 4

410000

196667

-213333 -332940 t o -93727

Treatment

95% Cl of diff.

Difference

t

P value

Summary

Day 1

7000

0.1914

P > 0.05

ns

Day 2

-68000

1.859

P > 0.05

ns

Day 3

-136667

3.737

P < 0.05

Day 4

-213333

5.834

P < 0.0001

pGL3
36000

C994A

****

pGL3 vs C994A
Treatment
Day 1
Day 2

127000

43000
59000

Difference
95% Cl of diff.
7000 -112607 to 126607
-68000 -187607 to 51607

Day 3
Day 4

283333
410000

153333
243333

-130000 -249607 t o -10393
-166667 -286273 t o -47060
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Difference

t

P value

Summary

7000

0.1914
1.859

P > 0.05
P > 0.05

3.555

P < 0.05

ns
ns
*

4.558

P < 0.001

Difference

Day 2

pGL3 Spacer mutant
36000
59000
127000
79000

23000
-48000

95% Cl of diff.
-96607 to 142607
-167607 to 71607

Day 3

283333

256667

-26667

-146273 to 92940

Day 4

410000

190000

Difference

t

P value

Summary

23000
-48000

0.6289

P > 0.05

ns

Day 2

1.313

P > 0.05

Day 3

-26667

0.7292

P > 0.05

Day 4

-220000

6.016

P < 0.0001

ns
ns
****

pGL3

RLD mutant

Difference

95% Cl of diff.

40000

-79607 to 159607

Treatment
Day 1
Day 2
Day 3

-68000
-130000

Day 4

-166667

***

pGL3 vs Spacer mutant
Treatment
Day 1

Treatment
Day 1

-220000-■ 339607 t o -100393

pGL3 vs RLD mutant
Treatment
Day 1

36000

76000

Day 2

127000

130000

Day 3

283333

330000

3000 -116607 to 122607
46667

-72940 to 166273

0.0 -119607 to 119607

410000

410000

Difference

t

P value

Summary

40000
3000

1.094

Day 2

0.08204

P > 0.05
P > 0.05

ns
ns

Day 3

46667

1.276

P > 0.05

ns

Day 4

0.0

0.0

P > 0.05

ns

pGL3

RLD 1-2
71000

Difference

95% Cl of diff.

35000

158000

31000

-84607 to 154607
-88607 to 150607

Day 4
Treatment
Day 1

pGL3 vs RLD 1-2
Treatment
Day 1
Day 2

36000
127000

Day 3

283333

346667

63333

-56273 to 182940

Day 4

410000

346667

-63333

-182940 to 56273

Difference

t

P value

Summary

35000
31000

0.9571
0.8477

P > 0.05
P > 0.05

ns
ns

Day 3

63333

1.732

P > 0.05

ns

Day 4

-63333

1.732

P > 0.05

ns

Treatment
Day 1
Day 2

pGL3 vs RLD 1-5
pGL3

RLD 1-5

Difference

95% Cl of diff.

Day 1

36000

63000

27000

-92607 to 146607

Day 2

127000

132000

Day 3

283333

350000

Treatment
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5000 -114607 to 124607
66667

-52940 to 186273

Day 4

410000

413333

3333 -116273 to 122940

Difference

t

P value

Summary

Day 1

27000

0.7383

P > 0.05

ns

Day 2

5000

0.1367

P > 0.05

ns

Day 3

66667

1.823

P > 0.05

ns

Day 4

3333

0.09115

P > 0.05

ns

Treatment
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